WO2011071135A1 - Dérivé d'oxazine - Google Patents
Dérivé d'oxazine Download PDFInfo
- Publication number
- WO2011071135A1 WO2011071135A1 PCT/JP2010/072193 JP2010072193W WO2011071135A1 WO 2011071135 A1 WO2011071135 A1 WO 2011071135A1 JP 2010072193 W JP2010072193 W JP 2010072193W WO 2011071135 A1 WO2011071135 A1 WO 2011071135A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- carbocyclic
- ring
- heterocyclic
- Prior art date
Links
- 0 CC*C1(C2=CC=CCC=CC=CC=C2)N=C(*)OC(*)C1(C)C Chemical compound CC*C1(C2=CC=CCC=CC=CC=C2)N=C(*)OC(*)C1(C)C 0.000 description 5
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- the present invention relates to a compound having an amyloid ⁇ production inhibitory effect and useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and / or deposition of amyloid ⁇ protein.
- Alzheimer's disease In the brain of Alzheimer's disease patients, insoluble spots (senile plaques) in which a peptide consisting of about 40 amino acids called amyloid ⁇ protein accumulates outside the nerve cells are widely observed. It is thought that Alzheimer's disease develops when this senile plaque kills nerve cells, and amyloid ⁇ protein degradation accelerators, amyloid ⁇ vaccines, and the like have been studied as therapeutic agents for Alzheimer's disease.
- Secretase is an enzyme that cleaves a protein called amyloid ⁇ precursor protein (APP) in cells to produce amyloid ⁇ protein.
- the enzyme responsible for the N-terminal generation of amyloid ⁇ protein is called ⁇ -site APP-cleaving enzyme 1, BACE1, and inhibiting this enzyme suppresses amyloid ⁇ protein production and treats Alzheimer's disease Or it could be a prophylactic agent.
- Patent Documents 1 to 11 describe a compound having a structure similar to that of the present invention and describe that it can be a therapeutic agent for Alzheimer's disease or Alzheimer-related symptoms. Also have a skeleton different from the compound of the present invention. Non-Patent Document 1 describes a compound having a structure similar to that of the present invention, but does not suggest any pharmaceutical activity.
- a compound having an inhibitory action on amyloid ⁇ production particularly a BACE1 inhibitory action, and useful as a therapeutic or preventive agent for diseases induced by production, secretion or deposition of amyloid ⁇ protein.
- the present invention provides the following items, for example.
- Ring A is a substituted carbocycle or a substituted or unsubstituted heterocycle
- R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxy Carbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted carbocyclic group or substituted or unsubstituted heterocyclic group
- R 2a and R 2b are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, substituted or unsubstitute
- R za and R zb are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted Substituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted Alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted
- ring A ′ and ring B are each independently a substituted or unsubstituted carbocyclic ring or a substituted or unsubstituted heterocyclic ring
- Z is -L 1 '-N (R 8) -L 2' - a
- L 1 ′ and L 2 ′ are each independently a single bond, substituted or unsubstituted alkylene (wherein the substituent is halogen, alkoxy, halogenoalkoxy, hydroxyalkoxy, alkoxyalkoxy, acyl, acyloxy, carboxy, alkoxycarbonyl, amino, Acylamino, alkylamino, imino, hydroxyimino, alkoxyimino, alkylthio, carbamoyl, alkylcarbamoyl, hydroxyalkylcarbamoyl, sulfamoyl, alkylsulfamoyl, alkylsulfinyl, alky
- R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxy Carbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted carbocyclic group or substituted or unsubstituted heterocyclic group, R 2a and R 2b are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl,
- ring A is Wherein ring A ′ and ring B are each independently a substituted or unsubstituted carbocyclic ring or a substituted or unsubstituted heterocyclic ring, Z is -L 1 -N (R 8 ) -L 2- , L 1 and L 2 are each independently a single bond, substituted or unsubstituted alkylene (wherein the substituents are halogen, alkoxy, halogenoalkoxy, hydroxyalkoxy, alkoxyalkoxy, acyl, acyloxy, carboxy, alkoxycarbonyl, amino, acylamino, Alkylamino, imino, hydroxyimino, alkoxyimino, alkylthio, carbamoyl, alkylcarbamoyl, hydroxyalkylcarbamoyl, sulfamoyl, alkylsulfamoyl, alkylsulfamoyl, alkyls
- Ring A is a substituted carbocycle or a substituted or unsubstituted heterocycle
- R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxy Carbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted carbocyclic group or substituted or unsubstituted heterocyclic group
- R 2a and R 2b are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl
- ring A is Wherein ring A ′ and ring B are each independently a substituted or unsubstituted carbocyclic ring or a substituted or unsubstituted heterocyclic ring, Z is -L 1 -N (R 8 ) -L 2- , L 1 and L 2 are each independently a single bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, R 8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl) A compound, Or a pharmaceutically acceptable salt thereof or a solvate thereof.
- Z is “—L 1 —N (R 8 ) -L 2 —”, “L 1 ” is bonded to ring B and “L 2
- ring A ′ and ring B are each independently a substituted or unsubstituted carbocyclic ring or a substituted or unsubstituted heterocyclic ring
- Z is —L 1 —C ( ⁇ O) N (R 8 ) —L 2 —, —L 1 —N (R 8 ) C ( ⁇ O) —L 2 — or —L 1 —N (R 8 ) —
- L 2- L 1 and L 2 are each independently a single bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene
- R 8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl) Or a pharmaceutically acceptable salt or solvate thereof according to item (1), (1-1) or
- Z represents “—L 1 —C ( ⁇ O) N (R 8 ) —L 2 —, —L 1 —N (R 8 ) C ( ⁇ O) —L 2 — or —L 1 —N (R 8 ).
- “-L 2 —” “L 1 ” is bonded to ring B, and “L 2 ” is bonded to ring A ′.
- R za and R zb are each independently hydrogen, halogen or a substituted or unsubstituted alkyl, and R 4a and R 4b are each independently hydrogen or a substituted or unsubstituted alkyl, (1), (1-1), (1-2) or (2) compound or a pharmaceutically acceptable salt thereof or a solvate thereof.
- R 3a , R 3b , R 4a and R 4b have the same meanings as item (1)
- a pharmaceutically acceptable salt or solvate thereof according to item (1), (1-1), (1-2) or (2).
- R 3a and R 4a have the same meanings as item (1), or a compound or a pharmaceutically acceptable salt thereof according to item (1), (1-1), (1-2) or (2) Salts or solvates thereof.
- Y 1 and Y 2 are each independently —C (R 5 ) ⁇ or —N ⁇ , and Q is as defined in item (1).
- Y 1 is —C (R 5 ) ⁇ or —N ⁇
- Y 2 is —C (R 5 ) (R 6 ) —, —N (R 7 ) —, —S—, —SO -, -SO 2 -or -O-
- Q and R 4c are as defined in item (1)), item (1), (1-1), (1-2) or (2)
- Y 1 is —C (R 5 ) (R 6 ) —, —N (R 7 ) —, —S—, —SO—, —SO 2 — or —O—
- Y 1 and Y 2 are each independently —C (R 5 ) (R 6 ) —, —N (R 7 ) —, —S—, —SO—, —SO 2 — or —
- a method for inhibiting BACE1 activity which comprises administering a compound described in 1. or a pharmaceutically acceptable salt thereof or a solvate thereof.
- a method for treating or preventing Alzheimer's disease which comprises administering the compound described in 1) or a pharmaceutically acceptable salt thereof or a solvate thereof.
- the compound of the present invention is useful as a therapeutic or prophylactic agent for diseases (such as Alzheimer's disease) induced by production, secretion or deposition of amyloid ⁇ protein.
- halogen includes fluorine, chlorine, bromine and iodine.
- alkyl refers to a linear or branched alkyl having 1 to 15 carbon atoms, such as 1 to 10 carbon atoms, such as 1 to 6 carbon atoms, such as 1 to 3 carbon atoms.
- the substituted or unsubstituted alkyl may be substituted with one or more groups selected from the substituent group ⁇ .
- the substituent group ⁇ is halogen, hydroxy, alkoxy, halogenoalkoxy, hydroxyalkoxy, alkoxyalkoxy, acyl, acyloxy, carboxy, alkoxycarbonyl, amino, acylamino, alkylamino, imino, hydroxyimino, alkoxyimino, alkylthio, Carbamoyl, alkylcarbamoyl, hydroxyalkylcarbamoyl, sulfamoyl, alkylsulfamoyl, alkylsulfinyl, alkylsulfonylamino, alkylsulfonylalkylamino, alkylsulfonylimino, alkylsulfinylamino, alkylsulfinylalkylamino, alkylsulfinylimino, cyano, nitro, carbon Cyclic and heterocyclic groups (where each carbo,
- Substituents of “substituted or unsubstituted alkoxy”, “substituted or unsubstituted alkoxycarbonyl”, “substituted or unsubstituted alkylthio”, “substituted or unsubstituted alkylsulfonyl” and “substituted or unsubstituted alkylsulfinyl” Includes one or more groups selected from the substituent group ⁇ .
- halogenoalkyl examples include trifluoromethyl, fluoromethyl, trichloromethyl and the like.
- halogenoalkoxy examples include trifluoromethoxy, fluoromethoxy, trichloromethoxy and the like.
- Alkylidene includes the above-mentioned divalent group of “alkyl” and includes, for example, methylidene, ethylidene, propylidene, isopropylidene, butylidene, pentylidene, hexylidene and the like.
- Alkenyl is a straight chain having 2 to 15 carbon atoms, such as 2 to 10 carbon atoms, such as 2 to 6 carbon atoms, such as 2 to 4 carbon atoms, having one or more double bonds at any position. Or includes branched alkenyl.
- alkenyl part of “alkenyloxy”, “alkenyloxycarbonyl”, “alkenylcarbonyl”, “alkoxyalkenyloxy”, “alkenylthio”, “alkenylamino”, “alkenylsulfonyl” and “alkenylsulfinyl” is the above “alkenyl”. It is the same.
- Alkynyl includes straight-chain or branched alkynyl having 2 to 10 carbon atoms, for example, 2 to 8 carbon atoms, for example 3 to 6 carbon atoms, having one or more triple bonds at any position. . Specifically, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl and the like are included. These may further have a double bond at an arbitrary position.
- alkynyl part of “alkoxyalkynyl”, “alkynyloxy”, “alkynyloxycarbonyl”, “alkynylcarbonyl”, “alkoxyalkynyloxy”, “alkynylthio”, “alkynylsulfinyl”, “alkynylsulfonyl” and “alkynylamino” The same as the above “alkynyl”.
- substituents of “substituted or unsubstituted amino”, “substituted or unsubstituted carbamoyl”, “substituted or unsubstituted thiocarbamoyl” and “substituted or unsubstituted sulfamoyl” include alkyl, acyl, hydroxy, alkoxy, Examples thereof include 1 to 2 groups selected from alkoxycarbonyl, carbocyclic group, heterocyclic group and the like.
- “Acyl” includes formyl, alkylcarbonyl having 1 to 10 carbon atoms, alkenylcarbonyl having 2 to 10 carbon atoms, alkynylcarbonyl having 2 to 10 carbon atoms, carbocyclic carbonyl and heterocyclic carbonyl.
- acyl part of “acyloxy” and “acylamino” is the same as the above “acyl”.
- the substituent of “substituted or unsubstituted acyl” and “substituted or unsubstituted acyloxy” includes one or more groups selected from substituent group ⁇ .
- the ring portion of carbocyclic carbonyl and heterocyclic carbonyl is substituted with one or more groups selected from alkyl, substituent group ⁇ , and alkyl substituted with one or more groups selected from substituent group ⁇ . It may be.
- Carbocyclic group includes cycloalkyl, cycloalkenyl, aryl, non-aromatic fused carbocyclic group, and the like.
- Cycloalkyl is a carbocyclic group having 3 to 10, for example, 3 to 8, for example, 4 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl. , Cyclononyl, cyclodecyl and the like.
- Cycloalkylalkyl “Cycloalkylalkyl”, “cycloalkyloxy”, “cycloalkylalkoxy”, “cycloalkylthio”, “cycloalkylamino”, “cycloalkylalkylamino”, “cycloalkylsulfamoyl”, “cycloalkylsulfonyl”,
- the cycloalkyl part of “cycloalkylcarbamoyl”, “cycloalkylalkylcarbamoyl”, “cycloalkylalkoxycarbonyl” and “cycloalkyloxycarbonyl” is the same as the above “cycloalkyl”.
- Cycloalkenyl includes those having one or more double bonds at any position in the ring of the cycloalkyl, specifically, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclo Examples include heptynyl, cyclooctynyl and cyclohexadienyl.
- Aryl includes phenyl, naphthyl, anthryl, phenanthryl, and the like, and particularly includes phenyl.
- non-aromatic fused carbocyclic group includes a non-aromatic group in which two or more cyclic groups selected from the above “cycloalkyl”, “cycloalkenyl” and “aryl” are condensed, and specifically Includes indanyl, indenyl, tetrahydronaphthyl, fluorenyl and the like.
- the carbocyclic portion of the “non-aromatic carbocycle” is the same as the above “cycloalkyl”, “cycloalkenyl”, and “non-aromatic fused carbocyclic group”, and more specifically, cyclopropane, cyclobutane, cyclo Including pentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclooctene and the like.
- Carbocycle “carbocycle oxy”, “carbocycle alkyl”, “carbocycle alkoxy”, “carbocycle alkoxycarbonyl”, “carbocycle thio”, “carbocycle amino”, “carbocycle alkylamino”, “ Carbon of carbocyclic carbonyl, carbocyclic sulfamoyl, carbocyclic sulfonyl, carbocyclic carbamoyl, carbocyclic alkylcarbamoyl, carbocyclic oxycarbonyl, carbocyclic sulfinyl, carbocyclic sulfonyl
- the ring portion is the same as the “carbocyclic group”.
- Arylalkyl “aryloxy”, “aryloxycarbonyl”, “arylalkoxycarbonyl”, “arylthio”, “arylamino”, “arylalkoxy”, “arylalkylamino”, “arylsulfonyl”, “arylsulfur”
- aryl moiety of “famoyl”, “arylcarbamoyl” and “arylalkylcarbamoyl” is the same as the above “aryl”.
- Heterocyclic group includes a heterocyclic group having one or more heteroatoms arbitrarily selected from O, S and N, specifically pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl.
- 5- to 6-membered heteroaryl such as, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, etc .; Dioxanyl, thilanyl, oxiranyl, oxetanyl, oxathiolanyl, azetidinyl, thianyl, thiazolidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, morpholinoyl, thiomorpholinyl, thiomorpholinyl, thiomorpholinyl,
- Heterocycle “heterocycle alkyl”, “heterocycle oxy”, “heterocycle thio”, “heterocycle carbonyl”, “heterocycle alkoxy”, “heterocycle amino”, “heterocycle sulfamoyl”, “heterocycle”
- the heterocyclic moiety of “sulfonyl”, “heterocyclic carbamoyl”, “heterocyclic oxycarbonyl”, “heterocyclic alkylamino”, “heterocyclic alkoxycarbonyl”, “heterocyclic alkylcarbamoyl” and “heterocyclic sulfinyl” is also referred to as “heterocyclic”.
- heterocyclic portion of the “non-aromatic heterocyclic ring” is the same as the heterocyclic portion of the above “non-aromatic heterocyclic group”, and more specifically, dioxane, thiirane, oxirane, oxetane, oxathiolane, azetidine, thiane.
- the bond of the above “heterocyclic group” may be located on any ring.
- Heteroaryl includes an aromatic cyclic group among the above “heterocyclic groups”.
- examples of the ring A include groups represented by the following formulae.
- ring A ′ and ring B are each independently a substituted or unsubstituted carbocyclic ring or a substituted or unsubstituted heterocyclic ring
- W 2 is O, S or N (R 8 )
- R 8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl;
- R 9 is hydrogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted
- L is each independently a single bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, and ring T is substituted with a group selected from substituent group ⁇
- substituted carbocycle “substituted or unsubstituted carbocycle”, “substituted or unsubstituted heterocycle”, “substituted or unsubstituted benzene” in ring A, ring A ′ and ring B ”,“ Substituted or unsubstituted pyridine ”,“ substituted or unsubstituted pyrimidine ”and“ substituted or unsubstituted pyrazine ”
- substituent group ⁇ for example, halogen, hydroxy, alkoxy, acyl, acyloxy, carboxy, alkoxycarbonyl, carbamoyl, amino, cyano, alkylamino and / or alkylthio, etc.
- substituted or unsubstituted carbocycle substituted or unsubstituted benzene
- substituted or unsubstituted heterocycle substituted or unsubstituted pyridine
- substituents of “substituted or unsubstituted pyrimidine” and “substituted or unsubstituted pyrazine” are substituted with one or more groups selected from halogen, cyano, hydroxy, nitro, carboxy, substituent group ⁇ , for example.
- substituent other than “—Z-ring B” in “substituted or unsubstituted carbocycle” or “substituted or unsubstituted heterocycle” in ring A include, for example, halogen, alkyl, alkenyl, alkynyl, alkoxy, Alkenyloxy, alkynyloxy or cyano.
- substituent of “substituted or unsubstituted carbocycle”, “substituted or unsubstituted benzene” or “substituted or unsubstituted heterocycle” in ring A ′ is, for example, halogen.
- Substituted or unsubstituted carbocycle “substituted or unsubstituted heterocycle”, “substituted or unsubstituted pyridine”, “substituted or unsubstituted pyrimidine”, or “substituted or unsubstituted pyrazine” in ring B
- substituents are halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy and cyano.
- Alkylene includes linear or branched divalent carbon chains having 1 to 10 carbon atoms, such as 1 to 6 carbon atoms, such as 1 to 3 carbon atoms. Specific examples include methylene, dimethylene, trimethylene, tetramethylene, methyltrimethylene and the like.
- alkylene part of “alkylenedioxy” is the same as the above “alkylene”.
- Alkenylene refers to a straight or branched divalent carbon chain having a double bond at any position and having 2 to 10, for example, 2 to 6, for example, 2 to 4 carbon atoms. Include. Specific examples include vinylene, propenylene, butenylene, butadienylene, methylpropenylene, pentenylene and hexenylene.
- Alkynylene is a linear or branched carbon having 2 to 10 carbon atoms, for example 2 to 6 carbon atoms, which has a triple bond at an arbitrary position and may further have a double bond, for example, And a divalent carbon chain having 2 to 4 carbon atoms. Specific examples include ethynylene, propynylene, butynylene, pentynylene and hexynylene.
- substituents selected from the substituent group ⁇ such as halogen, hydroxy Etc.
- Etc may be substituted at any position with one or more groups selected from the group consisting of alkyl substituted with one or more groups selected from substituent group ⁇ , unsubstituted alkyl, and substituent group ⁇ . Good.
- each symbol has the same meaning as item (1), and Q ′ is a substituted or unsubstituted carbocycle.
- Etc may be substituted at any position with one or more groups selected from the group consisting of alkyl substituted with one or more groups selected from substituent group ⁇ , unsubstituted alkyl, and substituent group ⁇ . Good.
- R za and R zb together with the carbon atom to which they are attached form a substituted or unsubstituted non-aromatic carbocycle or substituted or unsubstituted non-aromatic heterocycle
- R 3a and R 3b together with the carbon atom to which they are attached form a substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle and “R 4a and R 4b are The case of forming a substituted or unsubstituted carbocyclic ring or a substituted or unsubstituted heterocyclic ring together with the carbon atoms to be bonded is
- the “solvate” includes, for example, solvates and hydrates with an organic solvent, and can be converted into solvates and hydrates by a known method.
- Suitable solvates include solvates with acetone, 2-butanol, 2-propanol, ethanol, ethyl acetate, tetrahydrofuran, diethyl ether and the like.
- non-toxic and water-soluble hydrates or solvates for example, ethanol and the like
- it may be coordinated with any number of solvent molecules or water molecules.
- the compound represented by the formula (I) includes a pharmaceutically acceptable salt.
- alkali metals such as lithium, sodium or potassium
- alkaline earth metals such as calcium
- magnesium transition metals (such as zinc and iron), ammonium
- salts with organic bases and amino acids or inorganic acids (such as hydrochloric acid and sulfuric acid) , Nitric acid, hydrobromic acid, phosphoric acid or hydroiodic acid) and organic acids (acetic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, And malic acid, benzoic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid and the like.
- the compound represented by the formula (I) is not limited to a specific isomer, but all possible isomers (keto-enol isomer, imine-enamine isomer, diastereoisomer, optical isomer) And rotational isomers) and racemates.
- the compound represented by the formula (I) in which R 2a is hydrogen includes the following tautomers.
- the compound represented by the formula (I) has an asymmetric carbon atom and includes any of the following optical isomers. Preferably It is.
- Optical isomers of compounds of formula (I) can be obtained by known techniques such as chiral chromatography or formation of diastereomeric salts from optically active acids or bases.
- one or more hydrogen, carbon or other atoms of the compound of formula (I) may be replaced with isotopes of hydrogen, carbon or other atoms.
- Compounds of formula (I) include all radiolabeled forms of compounds of formula (I). Such “radiolabeled”, “radiolabeled” and the like of the compounds of formula (I) are each encompassed by the present invention and are useful as research and / or diagnostic tools in metabolic pharmacokinetic studies and binding assays. . It is also useful as a pharmaceutical product.
- Examples of isotopes that can be incorporated into the compounds of formula (I) of the present invention are 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, respectively.
- 35 S, 18 F, 123 I and 36 Cl include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine.
- the radiolabeled compound of the present invention can be prepared by methods well known in the art.
- a tritium labeled compound of formula (I) can be prepared by introducing tritium into a specific compound of formula (I) by, for example, catalytic dehalogenation reaction using tritium.
- This method involves reacting a compound of formula (I) with a suitably halogen-substituted precursor and tritium gas in the presence of a suitable catalyst, for example Pd / C, in the presence or absence of a base.
- a suitable catalyst for example Pd / C
- the 14C-labeled compound can be prepared by using a raw material having 14C carbon.
- the compounds of the present invention represented by the formulas (I) and (Ia) to (If) can be produced by the following method. In the following steps, when there are substituents that interfere with the reaction (for example, hydroxy, mercapto, amino, formyl, carbonyl, carboxyl, etc.), Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons ) Or the like, and the protecting group may be removed at a desired stage.
- substituents that interfere with the reaction for example, hydroxy, mercapto, amino, formyl, carbonyl, carboxyl, etc.
- Protective Groups in Organic Synthesis for example, hydroxy, mercapto, amino, formyl, carbonyl, carboxyl, etc.
- Theodora W Greene John Wiley & Sons
- the protecting group may be removed at a desired stage.
- First step In an enolate obtained by reacting a target ester such as ethyl propionate in the presence of a base such as lithium diisopropylamide in a solvent such as toluene, dichloromethane or tetrahydrofuran, or in a mixed solvent thereof, A titanium reagent such as chlorotitanium triisopropoxide is added, and a compound a that can be prepared by a known method is added, and then at ⁇ 80 ° C. to 30 ° C., preferably at ⁇ 80 ° C. to 0 ° C., for 0.1 to 24 hours, Preferably, compound b can be obtained by reacting for 0.1 to 12 hours.
- a target ester such as ethyl propionate
- a base such as lithium diisopropylamide
- a solvent such as toluene, dichloromethane or tetrahydrofuran, or in a mixed solvent thereof
- Second Step Compound b is converted into a Grignard reagent such as methylmagnesium bromide prepared in a solvent such as dioxane, tetrahydrofuran, ether, toluene or the like, or a mixed solvent thereof by a commercially available method, or borane or sodium borohydride. Then, a reducing agent such as lithium aluminum hydride is added and reacted at ⁇ 80 ° C. to 80 ° C., preferably ⁇ 20 ° C. to 30 ° C. for 0.5 hour to 48 hours, preferably 1 hour to 12 hours. c can be obtained.
- a reducing agent such as lithium aluminum hydride
- Third Step Compound c is subjected to 0 to 80 ° C. in the presence of an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid or trifluoroacetic acid in a solvent such as dioxane, methanol or dichloromethane or in a mixed solvent thereof.
- an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid or trifluoroacetic acid
- a solvent such as dioxane, methanol or dichloromethane or in a mixed solvent thereof.
- Compound d is added with an isothiocyanate having a protecting group (for example, benzoyl isothiocyanate) prepared by a commercially available or known method in a solvent such as dioxane, tetrahydrofuran, toluene, acetone, or a mixed solvent thereof.
- Compound e can be obtained by reacting at ⁇ 30 ° C. to 50 ° C., preferably ⁇ 10 ° C. to 25 ° C., for 0.1 to 12 hours, preferably for 0.1 to 3 hours.
- First step In a solvent such as toluene, dichloromethane, tetrahydrofuran or the like, or a mixed solvent thereof, a compound a that can be prepared by a known method is added to a Grignard reagent such as allylmagnesium bromide, and -80 ° C to 30 ° C, preferably Compound f can be obtained by reacting at -80 ° C. to 0 ° C. for 0.1 to 24 hours, preferably 0.1 to 12 hours.
- a Grignard reagent such as allylmagnesium bromide
- Compound g can be obtained by reacting at 0 ° C. to 80 ° C., preferably 0 ° C. to 30 ° C., for 0.5 to 48 hours, preferably for 1 to 24 hours.
- Third Step Compound g is added with an isocyanate having a protective group (for example, benzoyl isocyanate) prepared in a solvent such as dichloromethane, dioxane, tetrahydrofuran, toluene, acetone or the like, or a mixed solvent thereof by a commercially available or known method, and- Compound h can be obtained by reacting at 30 ° C. to 50 ° C., preferably ⁇ 10 ° C. to 25 ° C. for 0.1 hour to 12 hours, preferably 0.1 hour to 3 hours.
- a protective group for example, benzoyl isocyanate
- Compound h is added with a halogenium cation source such as iodine, bromine, N-bromosuccinimide (NBS) in a solvent such as dichloromethane, and -20 ° C to 40 ° C, preferably 0 ° C to 20 ° C.
- a base such as pyrrolidine, piperidine, piperazine, morpholine is added, and 20 ° C to 100 ° C, preferably 40 ° C to 80 ° C.
- Compound (Ib) can be obtained by reacting for 1 to 24 hours, preferably 1 to 12 hours.
- First step In an enolate obtained by reacting with a target carbonyl compound such as diethyl ketone in the presence of a base such as lithium diisopropylamide in a solvent such as toluene, dichloromethane, tetrahydrofuran, or a mixed solvent thereof, A titanium reagent such as chlorotitanium triisopropoxide is added, and a compound a that can be prepared by a known method is added, and the temperature is ⁇ 80 ° C. to 30 ° C., preferably ⁇ 80 ° C. to 0 ° C.
- compound i can be obtained by reacting for 0.1 to 12 hours.
- Second Step Compound i is subjected to 0 to 80 ° C. in the presence of an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid or trifluoroacetic acid in a solvent such as dioxane, methanol or dichloromethane or a mixed solvent thereof, preferably Can be obtained by reacting at 0 ° C. to 30 ° C. for 0.5 hour to 48 hours, preferably 1 hour to 24 hours.
- an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid or trifluoroacetic acid
- a solvent such as dioxane, methanol or dichloromethane or a mixed solvent thereof
- Third Step Compound j is added with an isocyanate having a protective group (for example, benzoyl isocyanate) prepared in a solvent such as dioxane, tetrahydrofuran, toluene, acetone or the like, or a mixed solvent thereof by a commercially available or known method, and -30
- the compound k can be obtained by reacting at a temperature of from 50 ° C. to 50 ° C., preferably from ⁇ 10 ° C. to 25 ° C. for 0.1 hour to 12 hours, preferably 0.1 hour to 3 hours.
- Step 1 Compound a which can be prepared by a known method is a target carbonyl compound such as cyclopentanone in the presence of a base such as lithium diisopropylamide in a solvent such as toluene, dichloromethane or tetrahydrofuran, or in a mixed solvent thereof.
- a target carbonyl compound such as cyclopentanone
- a base such as lithium diisopropylamide
- a solvent such as toluene, dichloromethane or tetrahydrofuran, or in a mixed solvent thereof.
- the compound is reacted at ⁇ 80 ° C. to 30 ° C., preferably ⁇ 80 ° C. to 0 ° C. for 0.1 hour to 24 hours, preferably 0.1 hour to 12 hours.
- l can be obtained.
- Second Step Compound 1 is dissolved in a solvent such as dioxane, methanol, dichloromethane, or a mixed solvent thereof in the presence of an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, trifluoroacetic acid, preferably 0 ° C. to 80 ° C., preferably Can be obtained by reacting at 0 ° C. to 30 ° C. for 0.5 to 48 hours, preferably 1 to 24 hours.
- a solvent such as dioxane, methanol, dichloromethane, or a mixed solvent thereof in the presence of an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, trifluoroacetic acid, preferably 0 ° C. to 80 ° C., preferably Can be obtained by reacting at 0 ° C. to 30 ° C. for 0.5 to 48 hours, preferably 1 to 24 hours.
- Third Step Compound m is added with a protecting group (for example, benzoyl isocyanate) having a protective group prepared by a commercially available or known method in a solvent such as dioxane, tetrahydrofuran, toluene, acetone or the like, or a mixed solvent thereof.
- the reaction is carried out at -50 ° C, preferably -10 ° C to 25 ° C for 0.1 hour to 12 hours, preferably 0.1 hour to 3 hours, followed by addition of concentrated sulfuric acid, concentrated nitric acid, etc.
- Compound (Id) can be obtained by reacting at -100 ° C, preferably 0 ° C-60 ° C, for 0.5-24 hours, preferably 1-12 hours.
- Step 1 Compound a, which can be prepared by a known method, is a target carbonyl compound such as cyclopentanone in a solvent such as toluene, dichloromethane or tetrahydrofuran, or in a mixed solvent thereof in the presence of a base such as lithium diisopropylamide.
- a target carbonyl compound such as cyclopentanone in a solvent such as toluene, dichloromethane or tetrahydrofuran, or in a mixed solvent thereof in the presence of a base such as lithium diisopropylamide.
- the compound is reacted at ⁇ 80 ° C. to 30 ° C., preferably ⁇ 80 ° C. to 0 ° C. for 0.1 hour to 24 hours, preferably 0.1 hour to 12 hours.
- n can be obtained.
- Second Step Compound n is added with a Grignard reagent such as methylmagnesium bromide prepared by a commercially available or known method in a solvent such as dioxane, tetrahydrofuran, ether, toluene or the like, or a mixed solvent thereof.
- a Grignard reagent such as methylmagnesium bromide prepared by a commercially available or known method in a solvent such as dioxane, tetrahydrofuran, ether, toluene or the like, or a mixed solvent thereof.
- an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, trifluoroacetic acid after reacting at -20 ° C, preferably -20 ° C to 30 ° C, for 0.5 hour to 48 hours, preferably 1 hour to 12 hours
- compound o can be obtained by reacting at 0 ° C. to 80 ° C., preferably 0 ° C. to 30 ° C., for
- Third Step Compound o is added with a protecting group (for example, benzoyl isocyanate) having a protective group prepared by a commercially available or known method in a solvent such as dioxane, tetrahydrofuran, toluene, acetone or the like, or a mixed solvent thereof.
- the reaction is carried out at -50 ° C, preferably -10 ° C to 25 ° C for 0.1 hour to 12 hours, preferably 0.1 hour to 3 hours, followed by addition of concentrated sulfuric acid, concentrated nitric acid, etc.
- Compound p can be obtained by reacting at -100 ° C., preferably 0 ° C.-60 ° C., for 0.5-24 hours, preferably 1-12 hours.
- Compound p is chlorinated in a solvent such as dichloromethane, tetrahydrofuran, toluene, etc. by adding oxalyl chloride, thionyl chloride, etc. and a catalytic amount of N, N-dimethylformamide, or 1-chloro-2-trimethylpropenylamine, etc.
- Compound (Ie) can be obtained by adding a reagent and reacting at 0 ° C. to 100 ° C., preferably 10 ° C. to 50 ° C., for 0.5 hour to 72 hours, preferably 0.5 hour to 6 hours. .
- First step In a solvent such as toluene, diethyl ether, tetrahydrofuran or the like, or in a mixed solvent thereof, Grignard reagent such as phenyl magnesium bromide having a hydroxyl group which may be protected at the ortho position, or protected at the ortho position
- Grignard reagent such as phenyl magnesium bromide having a hydroxyl group which may be protected at the ortho position, or protected at the ortho position
- Compound a which can be prepared by a known method, is added to a lithium reagent such as pyridyllithium having a good hydroxyl group, and the temperature is ⁇ 80 ° C. to 30 ° C., preferably ⁇ 80 ° C. to 0 ° C. for 0.1 hour to 24 hours, preferably
- the compound q can be obtained by reacting for 0.1 to 12 hours and then removing the protecting group of the hydroxyl group by a known method.
- Second Step Compound q is dissolved in a solvent such as dioxane, methanol, dichloromethane or the like, or a mixed solvent thereof in the presence of an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, trifluoroacetic acid, preferably 0 ° C. to 80 ° C.
- a solvent such as dioxane, methanol, dichloromethane or the like, or a mixed solvent thereof in the presence of an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, trifluoroacetic acid, preferably 0 ° C. to 80 ° C.
- an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, trifluoroacetic acid, preferably 0 ° C. to 80 ° C.
- Compound r is added with an isothiocyanate having a protecting group (for example, benzoyl isothiocyanate) prepared in a solvent such as dioxane, tetrahydrofuran, toluene, acetone or the like, or a mixed solvent thereof, commercially or by a known method, Compound s can be obtained by reacting at ⁇ 30 ° C. to 50 ° C., preferably ⁇ 10 ° C. to 25 ° C., for 0.1 to 12 hours, preferably for 0.1 to 3 hours.
- a protecting group for example, benzoyl isothiocyanate
- the optically active compound (I) is an optically active raw material, an asymmetric synthesis is carried out at an appropriate stage to obtain an optically active intermediate, or an intermediate or final product of each racemate is processed at an appropriate stage. It can be manufactured by optically dividing with Optical resolution methods include separation of optical isomers using an optically active column, kinetic optical resolution using enzymatic reactions, etc., diastereomers by salt formation using chiral acids and chiral bases. There are crystallization division, preferential crystallization method and the like.
- Ring A includes a substituted carbocycle or a substituted or unsubstituted heterocycle.
- Ring A ′ and Ring B are each independently a substituted or unsubstituted carbocyclic ring or a substituted or unsubstituted heterocyclic ring;
- W 2 is O, S or N (R 8 )
- R 8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted acyl;
- R 9 is hydrogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or
- L is each independently a single bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, and ring T is substituted with a group selected from substituent group ⁇
- substituent group ⁇ The other symbols are as defined above)
- L 1 and L 2 are each independently a single bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, R 8 includes hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted acyl.
- R 8 includes hydrogen
- Ring A ′ and ring B each independently include a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle.
- Ring A ′ is, for example, substituted or unsubstituted benzene
- ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine, or substituted or unsubstituted pyrazine.
- R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted Examples include alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted carbocyclic group or substituted or unsubstituted heterocyclic group .
- R 1 is, for example, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, cyano, substituted or unsubstituted carbocyclic group or substituted or unsubstituted heterocyclic group. Can be mentioned.
- R 1 is, for example, unsubstituted alkyl having 1 to 3 carbon atoms.
- R 2a and R 2b are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, or substituted or unsubstituted carbamoyl.
- R 2a and R 2b are hydrogen.
- R za and R zb are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or Unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl Carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl
- R za and R zb each independently include, for example, hydrogen, halogen, substituted or unsubstituted alkyl, or R za and R zb are Together with the carbon atoms to which it is attached, it forms a substituted or unsubstituted carbocycle.
- R za and R zb each independently include, for example, hydrogen, halogen, or substituted or unsubstituted alkyl.
- R 3a and R 3b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, Substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted Acyl, substituted or unsubstituted acyloxy, cyano, nitro,
- R 3a and R 3b are each independently, for example, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted Alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, Carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or
- substituent (rb) is a group in which R 3a is, for example, alkyl, R 3b is, for example, hydrogen, and broken line a indicates the absence of a bond.
- R 3a and R 3b are both hydrogen and the broken line a indicates the absence of a bond.
- R 3a is, for example, hydrogen and the broken line a indicates the presence of a bond.
- R 3a is, for example, alkyl and the broken line a indicates the presence of a bond.
- R 3c is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amino, substituted or unsubstituted Substituted carbamoyl, substituted or unsubstituted thiocarbamoyl, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclic oxycarbonyl A substituted or unsubstituted heterocyclic group, a substituted or unsubstituted heterocyclic oxycarbonyl, and when broken line b indicates the presence of a bond, R 3c is absent.
- substituent (rc) is a group in which R 3c is, for example, hydrogen and the broken line b indicates the absence of a bond.
- R 3c is, for example, hydrogen
- R 3c does not exist
- a group in which the broken line b indicates the presence of a bond can be mentioned.
- R 4a , R 4b and R 4c are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or Unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, Substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl,
- R 4a , R 4b and R 4c are each independently, for example, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted Or an unsubstituted alkenyl or a substituted or unsubstituted alkynyl, where R 4b is absent when the dashed line a indicates the presence of a bond, and R 4c is absent when the dashed line c indicates the presence of a bond.
- R 4a and R 4b include, for example, a group in which both are hydrogen.
- One embodiment of the substituent (rb) is a group in which R 4a and R 4b are both hydrogen and the broken line a indicates the absence of a bond.
- R 4a is, for example, hydrogen, and a group in which the broken line a indicates the presence of a bond is exemplified.
- R 4c is, for example, hydrogen, and a group in which the broken line c indicates the absence of a bond can be mentioned.
- One embodiment of the substituent (rc) includes a group in which R 4c is not present, for example, and the broken line c indicates the presence of a bond.
- the ring Q includes a substituted or unsubstituted carbocyclic ring or a substituted or unsubstituted heterocyclic ring.
- Y 1 and Y 2 are each independently —C (R 5 ) (R 6 ) —, —C (R 5 ) ⁇ , —N (R 7 ) —, —N ⁇ , —S—, —SO—, —SO 2 — or —O— can be mentioned.
- Y 1 and Y 2 are each independently, for example, —C (R 5 ) (R 6 ) — or —C (R 5 ) ⁇ .
- Y 3 and Y 4 are each independently —C (R 5 ) (R 6 ) —, —N (R 7 ) —, —S—, —SO—, —SO 2 — or —O— may be mentioned.
- Y 3 and Y 4 are each independently, for example, —C (R 5 ) (R 6 ) —.
- R 5 and R 6 are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted Substituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, Substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted
- R 5 and R 6 are each independently, for example, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted Or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, Cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substitute
- R 5 and R 6 are each independently, for example, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted Or unsubstituted acyl, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted amino, or substituted or unsubstituted carbamoyl.
- R 7 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted Alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted Substituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted substituted or unsubstituted alkenyl
- R 7 is for example hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or Unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted acyl, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfinyl Substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted carbamoyl, substituted or
- R 7 is for example hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, cyano, carboxy, substituted or unsubstituted Examples include alkoxycarbonyl or substituted or unsubstituted carbamoyl.
- Ring A ′ is a substituted or unsubstituted carbocycle (the substituent is, for example, a halogen)
- Ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine or substituted or unsubstituted pyrazine (the substituent is, for example, halogen, hydroxy, alkoxy, amino or cyano);
- R 1 is substituted or unsubstituted alkyl (more specifically, R 1 is unsubstituted alkyl);
- R 8 is hydrogen, substituted or unsubstituted alkyl or substituted or unsubstituted acyl (more specifically, R 8 is hydrogen);
- R za and R zb are each independently hydrogen or substituted or unsubstituted alkyl (more specifically, R za and R zb are both hydrogen)) Is mentioned.
- Ring A ′ is a substituted or unsubstituted carbocycle (substituent is, for example, halogen) or substituted or unsubstituted thiophene (substituent is, for example, halogen);
- Ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine or substituted or unsubstituted pyrazine (the substituent is, for example, halogen, hydroxy, alkyl, halogenoalkyl, alkynyl, alkoxy, halogenoalkoxy, amino or cyano )
- R 1 is substituted or unsubstituted alkyl (more specifically, R 1 is unsubstituted alkyl);
- R 8 is hydrogen, substituted or unsubstituted alkyl or substituted or unsubstituted acyl (more specifically, R 8 is hydrogen)
- Ring A ′ is a substituted or unsubstituted carbocycle (the substituent is, for example, a halogen)
- Ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine or substituted or unsubstituted pyrazine (the substituent is, for example, halogen, hydroxy, alkyl, halogenoalkyl, alkoxy, halogenoalkoxy, amino or cyano).
- R 1 is substituted or unsubstituted alkyl (more specifically, R 1 is unsubstituted alkyl);
- R 3 is hydrogen or substituted or unsubstituted alkyl (more specifically, R 3 is unsubstituted alkyl);
- R 8 is hydrogen, substituted or unsubstituted alkyl or substituted or unsubstituted acyl (more specifically, R 8 is hydrogen)) Is mentioned.
- Ring A is A compound,
- Ring B is Wherein R b1 and R b2 are each independently hydrogen, chloro, fluoro, methoxy, butynyloxy, cyano, amino or carbamoyl.
- R b1 and R b2 are each independently hydrogen, chloro, fluoro, methoxy, butynyloxy, cyano, amino or carbamoyl.
- a compound, A compound in which the combination of ring B, R b1 and R b2 (B, R b1 , R b2 ) is as follows.
- ring B (B1, hydrogen, hydrogen) (hereinafter, ring B is b1), (B1, hydrogen, chloro) (hereinafter, ring B is b2), (B1, hydrogen, fluoro) (hereinafter, ring B is b3), (B1, hydrogen, methoxy) (hereinafter, ring B is b4), (B1, hydrogen, butynyloxy) (hereinafter, ring B is b5), (B1, hydrogen, cyano) (hereinafter, ring B is b6), (B1, hydrogen, amino) (hereinafter, ring B is b7), (B1, hydrogen, carbamoyl) (hereinafter, ring B is b8), (B1, chloro, hydrogen) (hereinafter, ring B is b9), (B1, chloro, chloro) (hereinafter, ring B is b10), (B1, chloro, fluoro) (hereinafter, ring B is b11), (B1, chloro, methoxy
- ring B (B3, hydrogen, hydrogen) (hereinafter, ring B is b60), (B3, hydrogen, chloro) (hereinafter, ring B is b61), (B3, hydrogen, fluoro) (hereinafter, ring B is b62), (B3, hydrogen, methoxy) (hereinafter, ring B is b63), (B3, hydrogen, butynyloxy) (hereinafter, ring B is b64), (B3, hydrogen, cyano) (hereinafter, ring B is b65), (B3, hydrogen, amino) (hereinafter, ring B is b66), (B3, hydrogen, carbamoyl) (hereinafter, ring B is assumed to be b67), (B3, chloro, hydrogen) (hereinafter, ring B is b68), (B3, chloro, chloro) (hereinafter, ring B is b69), (B3, chloro, fluoro) (hereinafter, ring B is b70), (B3, chloro,
- a compound in which the combination of ring B and R b1 (B, R b1 ) is as follows.
- a combination of ring A and ring B (r, A, b) is as follows. (r1, A1, b1), (r1, A1, b2), (r1, A1, b3), (r1, A1, b4), (r1, A1, b5), (r1, A1, b6), (r1 , A1, b7), (r1, A1, b8), (r1, A1, b9), (r1, A1, b10), (r1, A1, b11), (r1, A1, b12), (r1, A1 , b13), (r1, A1, b14), (r1, A1, b15), (r1, A1, b16), (r1, A1, b17), (r1, A1, b18), (r1, A1, b19 ), (r1, A1, b20), (r1, A1, b21), (r1, A1, b22), (r1, A1, b23), (r1, A1, b24), (r1, A1, A1, b9
- the compound of the present invention is useful for diseases induced by production, secretion or deposition of amyloid ⁇ protein.
- diseases induced by production, secretion or deposition of amyloid ⁇ protein For example, Alzheimer type dementia (Alzheimer's disease, Alzheimer type senile dementia etc.), Down's syndrome, memory disorder, prion disease (Kreuz's disease) Felt-Jakob disease, etc.), mild cognitive impairment (MCI), Dutch hereditary amyloid cerebral hemorrhage, cerebral amyloid angiopathy, other degenerative dementia, mixed vascular dementia, dementia associated with Parkinson's disease, progression Treatment and / or prevention of dementia associated with supranuclear paralysis, dementia associated with corticobasal degeneration, diffuse Lewy body Alzheimer's disease, age-related macular degeneration, Parkinson's disease, amyloid angiopathy, etc.
- treatment of Alzheimer's disease includes prevention of MCI severity and prevention of familial Alzheimer's disease.
- pharmaceutical composition for treating Alzheimer's disease includes a pharmaceutical composition for preventing MCI from becoming severe, a pharmaceutical composition for preventing the onset of familial Alzheimer's disease, and the like.
- the compound of the present invention has high inhibitory activity against BACE1 and / or high selectivity to other enzymes, and therefore can be a pharmaceutical with reduced side effects. Furthermore, since it has a high inhibitory effect on amyloid ⁇ production in cell systems, and particularly has a high inhibitory effect on amyloid ⁇ production in the brain, it can be an excellent pharmaceutical product. Moreover, it can become a pharmaceutical with a wider safety margin with respect to a side effect by setting it as the optically active substance which has appropriate stereochemistry.
- the compound of the present invention has high metabolic stability, high solubility, high oral absorption, good bioavailability, good clearance, high brain transferability, long half-life, non-protein binding rate Also has advantages such as high HERG channel inhibition, low CYP inhibition, low CYP MBI (Mechanism-based inhibition) and / or negative Ames test.
- the compound of the present invention When the compound of the present invention is administered, it may be used in combination with other drugs (for example, other Alzheimer's disease treatment or prevention agents such as acetylcholinesterase).
- other drugs for example, other Alzheimer's disease treatment or prevention agents such as acetylcholinesterase.
- antidementia drugs such as donepezil hydrochloride, tacrine, galantamine, rivastigmine, zanapezil, memantine, and vinpocetine.
- the compound of the present invention When the compound of the present invention is administered to humans, it can be administered orally as powders, granules, tablets, capsules, pills, liquids, etc. or parenterally as injections, suppositories, transdermal absorption agents, inhalants, etc. Can be administered.
- excipients, binders, wetting agents, disintegrants, lubricants and other pharmaceutical additives suitable for the dosage form may be mixed with an effective amount of the present compound as necessary to obtain a pharmaceutical preparation. it can.
- the dose varies depending on the disease state, administration route, patient age, or body weight, but when administered orally to an adult, it is usually 0.1 ⁇ g to 1 g / day, preferably 0.01 to 200 mg / day. In the case of parenteral administration, it is usually 1 ⁇ g to 10 g / day, preferably 0.1 to 2 g / day.
- compound (9) (3.00 g) prepared by the method described in WO2009 / 151098 was dissolved in tetrahydrofuran (30 ml) and cooled in a dry ice-acetone bath.
- 2-Methylallyl magnesium chloride (0.5 mol / L THF solution, 85.0 ml) was added dropwise at -78 ° C, and the mixture was stirred at -78 ° C for 2 hours.
- a saturated aqueous ammonium chloride solution and water were added to the reaction mixture, and the mixture was extracted with ethyl acetate, and washed successively with water and saturated brine.
- N, N-Diisopropylethylamine (2.42 ml) and methyl iodide (1.97 g) were added to a solution of the sixth step compound (15) (4.61 g) in acetonitrile (20 ml), and the mixture was stirred at room temperature for 24 hours.
- the solvent was distilled off under reduced pressure, water was added to the residue, and the mixture was extracted with ethyl acetate.
- the organic layer was washed successively with 1 mol / L hydrochloric acid, water, saturated aqueous sodium hydrogen carbonate, water and saturated brine, and dried over anhydrous magnesium sulfate.
- the solvent was distilled off under reduced pressure to obtain Compound (16) (4.36 g).
- Example 4 Synthesis of Compound (I-55) First Step Compound (20) (30 g) was dissolved in chloroform (60 ml), trimethylaluminum (33.3 g) and bromine (12.9 ml) were added at 0 ° C., and the mixture was stirred at room temperature for 1 hour. Thereafter, the temperature was raised to 50 ° C. and the mixture was stirred for 2 hours, then trimethylaluminum (16.0 g) was added, and the mixture was stirred for 1 hour. The temperature of the reaction solution was returned to room temperature, sodium acetate was added, and the mixture was filtered through Celite. This was extracted with chloroform and dried over sodium sulfate.
- RT retention time (minutes)
- D deuterium
- the substrate peptide was synthesized by reacting biotin-XSEVNLDAEFRHDSGC (Peptide Institute) with cryptate TBPCOOH mono SMP (CIS bio international).
- the final concentration of substrate peptide is 18 nmol / L
- the final concentration of recombinant human BACE1 is 7.4 nmol / L
- the reaction buffer is sodium acetate buffer (50 mmol / L sodium acetate pH 5.0, 0.008% Triton X-100). Using.
- the enzyme activity was determined from the count rate at each measurement wavelength (10000 ⁇ count 665 / count 620), and the dose (IC 50 ) that inhibits the enzyme activity by 50% was calculated.
- Compound I-1 IC 50 value 0.0473 ⁇ mol / L
- Compound I-2 IC 50 value 0.027 ⁇ mol / L
- Compound I-6 IC 50 value 0.054 ⁇ mol / L
- Compound I-53 IC 50 value 0.046 ⁇ mol / L
- Compound I-54 IC 50 value 0.097 ⁇ mol / L
- Compounds I-3, 4, 5, 7 to 11, 52, and 55 to 60 also had an IC 50 value of 30 ⁇ mol / L or less.
- Neuroblastoma SH-SY5Y cells (SH / APPwt) overexpressing human wild-type ⁇ APP were adjusted to 8 ⁇ 105 cells / mL and plated on 96-well culture plates (Falcon) at 150 ⁇ l per well. The cells were cultured at 37 ° C. in a 5% carbon dioxide incubator for 2 hours. Thereafter, a solution in which a test compound (DMSO: dimethyl sulfoxide solution) was added and suspended in advance to be a 2 ⁇ l / 50 ⁇ l medium was added to the cell solution.
- DMSO dimethyl sulfoxide solution
- the final DMSO concentration was 1%, and the cell culture solution was 200 ⁇ l. After 24 hours of incubation from the addition of the test compound, 100 ⁇ l of the culture supernatant was collected and the amount of A ⁇ contained therein was measured.
- the amount of A ⁇ was measured by culturing 10 ⁇ l of homogeneous time-resolved fluorescence (HTRF) measurement reagent (Amyloid ⁇ 1-40 peptide; IBA Molecular Holding, SA) on a 384 well half area plate (black plate; manufactured by Coaster). 10 ⁇ l of the supernatant was added, mixed, and left at 4 ° C. overnight protected from light. Thereafter, the fluorescence intensity (excitation wavelength: 337 nm, measurement wavelengths: 620 nm and 665 nm) was measured using a Wallac 1420 multilabel counter (Perkin Elmer life sciences).
- HTRF time-resolved fluorescence
- the amount of A ⁇ was determined from the count rate of each measurement wavelength (10000 ⁇ count 665 / count 620), and the dose that inhibits A ⁇ production by 50% (IC50) was calculated from at least 6 different doses.
- Compound I-1 IC 50 value 0.0155 ⁇ mol / L
- Test Example 3 Rat brain ⁇ -amyloid reducing action
- the test compound is suspended in 0.5% methylcellulose, prepared to a final concentration of 2 mg / mL, and orally administered to male Crj: SD rats (7-9 weeks old) to 10 mg / kg. .
- the base control group is administered with 0.5% methylcellulose alone, and 3 to 8 animals are administered in each group.
- the brain is removed, the cerebral hemisphere is isolated, weighed, and then immediately frozen in liquid nitrogen and stored at ⁇ 80 ° C. until the date of extraction.
- the frozen cerebral hemisphere was transferred to a Teflon (registered trademark) homogenizer under ice-cooling, and an extraction buffer (1% CHAPS ( ⁇ 3-[(3-chloroamidopropyl) dimethylammonio] -1-propane) having a volume 5 times its weight was used. Sulfonate ⁇ ), 20 mmol / L Tris-HCl (pH 8.0), 150 mmol / L NaCl and Complete (Roche) protease inhibitor) are added, and the mixture is repeatedly homogenized for 2 minutes to solubilize. The suspension is transferred to a centrifuge tube and left on ice for 3 hours or more, and then centrifuged at 100,000 ⁇ g, 4 ° C.
- ⁇ -amyloid 40 manufactured by Wako Pure Chemical Industries, Ltd., product number 294-62501.
- the ELISA measurement is performed according to the attached instructions.
- the decreasing effect is calculated as the ratio of the base control group of each test to ⁇ -amyloid 40 in the brain.
- the CYP3A4 fluorescent MBI test is a test for examining the enhancement of CYP3A4 inhibition of a compound by metabolic reaction, and 7-benzyloxytrifluoromethylcoumarin (7-BFC) is debenzylated by CYP3A4 enzyme using E. coli-expressed CYP3A4 as an enzyme.
- the reaction for producing a fluorescent metabolite 7-hydroxytrifluoromethylcoumarin (HFC) was performed as an index.
- reaction conditions are as follows: substrate, 5.6 ⁇ mol / L 7-BFC; pre-reaction time, 0 or 30 minutes; reaction time, 15 minutes; reaction temperature, 25 ° C. (room temperature); CYP3A4 content (E. coli expression enzyme), Pre-reaction 62.5 pmol / mL, reaction 6.25 pmol / mL (10-fold dilution); test drug concentration, 0.625, 1.25, 2.5, 5, 10, 20 ⁇ mol / L (6 points) ).
- the control (100%) was obtained by adding DMSO, which is a solvent in which the drug was dissolved, to the reaction system, and the residual activity (%) at each concentration with the test drug solution added was calculated.
- the IC 50 was calculated by inverse estimation using a logistic model. The case where the difference in IC 50 values was 5 ⁇ M or more was designated as (+), and the case where it was 3 ⁇ M or less was designated as ( ⁇ ).
- Compound I-52 ( ⁇ )
- Test Example 5 CYP inhibition test
- CYP1A2 O-deethylation of 7-ethoxyresorufin
- methyl tolbutamide as a typical substrate metabolic reaction of the major human CYP5 species (CYP1A2, 2C9, 2C19, 2D6, 3A4) -Index of hydroxylation (CYP2C9), mephenytoin 4'-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), and terfenadine hydroxylation (CYP3A4).
- the degree of inhibition by the test compound was evaluated.
- reaction conditions are as follows: substrate, 0.5 ⁇ mol / L ethoxyresorufin (CYP1A2), 100 ⁇ mol / L tolbutamide (CYP2C9), 50 ⁇ mol / L S-mephenytoin (CYP2C19), 5 ⁇ mol / L dextromethorphan (CYP2D6), 1 ⁇ mol / L terfenadine (CYP3A4); reaction time, 15 minutes; reaction temperature, 37 ° C .; enzyme, pooled human liver microsomes 0.2 mg protein / mL; test drug concentration 1, 5, 10, 20 ⁇ mol / L (4 points) ).
- resorufin CYP1A2 metabolite
- CYP1A2 metabolite resorufin in the supernatant of the centrifugation was collected with a fluorescent multilabel counter
- tolbutamide hydroxide CYP2C9 metabolite
- mephenytoin 4 ′ hydroxide CYP2C19 metabolite
- Dextrorphan CYP2D6 metabolite
- terfenadine alcohol CYP3A4 metabolite
- the control (100%) was obtained by adding only DMSO, which is a solvent in which the drug was dissolved, to the reaction system, and the residual activity (%) at each concentration of the test drug solution was calculated.
- the IC 50 was calculated by inverse estimation using a logistic model.
- Compound I-53 5 types> 20 ⁇ M
- Test Example 6 FAT test Inoculate 20 ⁇ L of Salmonella typhimurium TA98 strain and TA100 strain in a cryopreserved 10 mL liquid nutrient medium (2.5% Oxoid nutrient broth No. 2) and incubate at 37 ° C for 10 hours before shaking.
- TA98 strain 9 mL of the bacterial solution is centrifuged (2000 ⁇ g, 10 minutes) to remove the culture solution, and 9 mL of Micro F buffer solution (K 2 HPO 4 : 3.5 g / L, KH 2 PO 4 : 1 g /) L, (NH 4 ) 2 SO 4 : 1 g / L, trisodium citrate dihydrate: 0.25 g / L, MgSO 4 ⁇ 7H 2 0: 0.1 g / L), and 110 mL of Exposure Add to medium (BioF: 8 ⁇ g / mL, histidine: 0.2 ⁇ g / mL, glucose: MicroF buffer solution containing 8 mg / mL), TA100 strain to 3.16 mL bacterial solution added to 120 mL of Exposure medium and test bacterial solution To prepare.
- Micro F buffer solution K 2 HPO 4 : 3.5 g / L, KH 2 PO 4 : 1 g /) L, (NH
- Test substance DMSO solution (maximum dose 50 mg / mL to 8-fold dilution at 2-fold common ratio), DMSO as negative control, 50 ⁇ g / mL 4-nitroquinoline for TA98 strain under non-metabolic activation conditions as positive control -1-oxide DMSO solution, for TA100 strain, 0.25 ⁇ g / mL 2- (2-furyl) -3- (5-nitro-2-furyl) acrylamide DMSO solution, for metabolic activation conditions, for TA98 strain 40 ⁇ g / mL 2-aminoanthracene DMSO solution and 20 ⁇ g / mL 2-aminoanthracene DMSO solution for the TA100 strain, respectively, and test bacterial solution 588 ⁇ L (under metabolic activation conditions, test bacterial solution 498 ⁇ L and S9 mix 90 ⁇ L) and incubate at 37 ° C for 90 minutes with shaking.
- Test Example 8 Metabolic stability test
- the target compound is allowed to react for a certain period of time, and the residual rate is calculated by comparing the reaction sample with the unreacted sample to evaluate the degree of metabolism in the liver.
- the absolute value of the maximum tail current is measured from the obtained I Kr using the analysis software (DataXpress ver. 1, Molecular Devices Corporation) based on the current value at the holding membrane potential. Further, the inhibition rate with respect to the maximum tail current before application of the test substance is calculated, and compared with the medium application group (0.1% dimethyl sulfoxide solution), the influence of the test substance on I Kr is evaluated.
- Test Example 10 Powder solubility test
- JP-1 solution 2.0 g sodium chloride, 7.0 mL hydrochloric acid to add 1000 mL
- JP-2 solution 500 mL pH 6.8 phosphate buffer, 500 mL water
- TCA sodium taurocholate
- JP-2 solution water was added to TCA 1.08 g to make 100 mL
- 200 ⁇ L each was added.
- If dissolved after adding the test solution add bulk powder as appropriate. Seal and shake at 37 ° C for 1 hour. Filter, add 100 ⁇ L of methanol to 100 ⁇ L of each filtrate and dilute 2 times. Change the dilution factor as necessary. Check for bubbles and precipitates, seal and shake. Quantify using HPLC with the absolute calibration curve method.
- Intravenous administration was carried out from the tail vein using a syringe with an injection needle.
- Evaluation item Blood was collected over time, and the plasma drug concentration was measured using LC / MS / MS.
- Compound I-53 80.4%
- Rats are intravenously administered at a dose of 0.5 mg / mL / kg, and after 30 minutes, they are exsanguinated by whole blood collection from the lower aorta under isoflurane anesthesia. The brain is then removed and 20-25% homogenate is prepared with distilled water. On the other hand, the obtained blood is made into plasma after centrifugation. Thereafter, control plasma is added to the brain sample and control brain is added to the plasma sample at a ratio of 1: 1, and each sample is measured using LC / MS / MS. The obtained area ratio (brain / plasma) at the time of measurement is defined as the brain Kp value.
- Formulation Example 1 A granule containing the following ingredients is produced.
- Formulation Example 2 A capsule filling granule containing the following ingredients is produced.
- Formulation Example 3 A tablet containing the following ingredients is produced.
- Formulation Example 4 The following ingredients are heated and mixed and then sterilized to give an injection.
- the compound of the present invention can be a useful drug as a therapeutic or prophylactic agent for diseases induced by production, secretion and / or deposition of amyloid ⁇ protein.
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10836054.6A EP2511268B2 (fr) | 2009-12-11 | 2010-12-10 | Dérivé d'oxazine |
AU2010328975A AU2010328975B2 (en) | 2009-12-11 | 2010-12-10 | Oxazine derivative |
RU2012129168/04A RU2012129168A (ru) | 2009-12-11 | 2010-12-10 | Производные оксазина |
BR112012013854A BR112012013854A2 (pt) | 2009-12-11 | 2010-12-10 | derivados de oxazina. |
MX2012006491A MX2012006491A (es) | 2009-12-11 | 2010-12-10 | Derivados de oxazina. |
CN2010800648635A CN102834384A (zh) | 2009-12-11 | 2010-12-10 | *嗪衍生物 |
UAA201208561A UA110467C2 (uk) | 2009-12-11 | 2010-12-10 | Похідні оксазину |
JP2011545253A JPWO2011071135A1 (ja) | 2009-12-11 | 2010-12-10 | オキサジン誘導体 |
CA2783958A CA2783958A1 (fr) | 2009-12-11 | 2010-12-10 | Derive d'oxazine |
ES10836054T ES2590038T5 (es) | 2009-12-11 | 2010-12-10 | Derivado de oxazina |
US13/513,839 US8999980B2 (en) | 2009-12-11 | 2010-12-10 | Oxazine derivatives |
ZA2012/03777A ZA201203777B (en) | 2009-12-11 | 2012-05-23 | Oxazine derivative |
US14/627,700 US9290466B2 (en) | 2009-12-11 | 2015-02-20 | Oxazine derivatives |
US15/041,683 US9656974B2 (en) | 2009-12-11 | 2016-02-11 | Oxazine derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-282184 | 2009-12-11 | ||
JP2009282184 | 2009-12-11 | ||
JP2010-237030 | 2010-10-22 | ||
JP2010237030 | 2010-10-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/513,839 A-371-Of-International US8999980B2 (en) | 2009-12-11 | 2010-12-10 | Oxazine derivatives |
US14/627,700 Continuation US9290466B2 (en) | 2009-12-11 | 2015-02-20 | Oxazine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011071135A1 true WO2011071135A1 (fr) | 2011-06-16 |
Family
ID=44145678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/072193 WO2011071135A1 (fr) | 2009-12-11 | 2010-12-10 | Dérivé d'oxazine |
Country Status (15)
Country | Link |
---|---|
US (3) | US8999980B2 (fr) |
EP (1) | EP2511268B2 (fr) |
JP (2) | JPWO2011071135A1 (fr) |
KR (1) | KR20120104570A (fr) |
CN (1) | CN102834384A (fr) |
AU (1) | AU2010328975B2 (fr) |
BR (1) | BR112012013854A2 (fr) |
CA (1) | CA2783958A1 (fr) |
ES (1) | ES2590038T5 (fr) |
MX (1) | MX2012006491A (fr) |
RU (1) | RU2012129168A (fr) |
TW (1) | TWI488852B (fr) |
UA (1) | UA110467C2 (fr) |
WO (1) | WO2011071135A1 (fr) |
ZA (2) | ZA201203777B (fr) |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168630B2 (en) | 2007-04-24 | 2012-05-01 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
WO2012057248A1 (fr) | 2010-10-29 | 2012-05-03 | 塩野義製薬株式会社 | Dérivé de naphtyridine |
WO2012057247A1 (fr) | 2010-10-29 | 2012-05-03 | 塩野義製薬株式会社 | Dérivé d'aminodihydropyrimidine fusionnée |
US8173642B2 (en) | 2005-10-25 | 2012-05-08 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
US8183252B2 (en) | 2003-12-15 | 2012-05-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US8207164B2 (en) | 2009-07-24 | 2012-06-26 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
US20120202803A1 (en) * | 2011-02-08 | 2012-08-09 | Hans Hilpert | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1h-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as bace1 and/or bace2 inhibitors |
WO2012147762A1 (fr) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | Dérivé de pyridine et inhibiteur de bace-1 le contenant |
WO2012147763A1 (fr) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | Dérivé d'oxazine et inhibiteur de bace 1 le contenant |
WO2012156284A1 (fr) * | 2011-05-16 | 2012-11-22 | F. Hoffmann-La Roche Ag | 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2 |
WO2012168164A1 (fr) * | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | Halogéno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2 |
WO2012168175A1 (fr) * | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | [1,3]oxazines |
US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
WO2013041499A1 (fr) * | 2011-09-21 | 2013-03-28 | F. Hoffmann-La Roche Ag | N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydrocyclopenta[e][1,3]oxazin-4-yl)phényl)amides utilisés comme inhibiteurs de la bace1 |
WO2013083556A1 (fr) * | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Dérivés de 5-(3-aminophényl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine |
US8524897B2 (en) | 2011-01-12 | 2013-09-03 | Novartis Ag | Crystalline oxazine derivative |
US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US8569310B2 (en) | 2009-10-08 | 2013-10-29 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use |
WO2014001228A1 (fr) | 2012-06-26 | 2014-01-03 | F. Hoffmann-La Roche Ag | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 |
US8637508B2 (en) | 2011-01-13 | 2014-01-28 | Novartis Ag | Heterocyclic derivatives and their use in the treatment of neurological disorders |
US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
WO2014059185A1 (fr) | 2012-10-12 | 2014-04-17 | Amgen Inc. | Composés amino-dihydrothiazine et amino-dioxydo dihydrothiazine en tant qu'antagonistes de bêta-sécrétase et procédés d'utilisation |
US8703785B2 (en) | 2008-10-22 | 2014-04-22 | Shionogi & Co., Ltd. | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity |
JP2014510769A (ja) * | 2011-04-11 | 2014-05-01 | エフ.ホフマン−ラ ロシュ アーゲー | Bace1及び/又はbace2阻害剤としての1,3−オキサジン |
WO2014065434A1 (fr) * | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1 |
US8729071B2 (en) | 2009-10-08 | 2014-05-20 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use |
WO2014078314A1 (fr) | 2012-11-15 | 2014-05-22 | Amgen Inc. | Composés d'amino-oxazine et d'amino-dihydrothiazine jouant le rôle de modulateurs de bêta-sécrétase et procédés d'utilisation |
WO2014134341A1 (fr) | 2013-03-01 | 2014-09-04 | Amgen Inc. | Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants |
WO2014138484A1 (fr) | 2013-03-08 | 2014-09-12 | Amgen Inc. | Composés à base de 1,3-oxazin-2-amine fusionnée avec du cyclopropyle perfluoré utilisables en tant qu'inhibiteurs de la bêta-sécrétase et leurs procédés d'utilisation |
JP2015504906A (ja) * | 2012-01-26 | 2015-02-16 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | フルオロメチル−5,6−ジヒドロ−4h−[1,3]オキサジン |
US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
WO2015156421A1 (fr) | 2014-04-11 | 2015-10-15 | Shionogi & Co., Ltd. | Dérivés de dihydrothiazine et de dihydrooxazine présentant une activité inhibitrice de bace1 |
US9163011B2 (en) | 2011-08-25 | 2015-10-20 | Novartis Ag | Oxazine derivatives and their use in the treatment of disease |
US9181236B2 (en) | 2011-08-22 | 2015-11-10 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
WO2016012384A1 (fr) | 2014-07-22 | 2016-01-28 | F. Hoffmann-La Roche Ag | Amidines de trifluormethyloxazine utilisées comme inhibiteurs de bace1 |
US9346811B2 (en) | 2011-03-01 | 2016-05-24 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
JP2016515638A (ja) * | 2013-04-11 | 2016-05-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bace1阻害剤 |
US9489013B2 (en) | 2012-12-20 | 2016-11-08 | Merck Sharp & Dohme Corp. | C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use |
US9550762B2 (en) | 2014-08-08 | 2017-01-24 | Amgen, Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
US9580433B2 (en) | 2013-06-12 | 2017-02-28 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
WO2017061534A1 (fr) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dérivés de dihydrothiazine |
US9751886B2 (en) | 2013-06-12 | 2017-09-05 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
US9828350B2 (en) | 2010-06-09 | 2017-11-28 | Janssen Pharmaceutica Nv | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) |
US9834559B2 (en) | 2013-06-12 | 2017-12-05 | Janssen Pharmaceutica Nv | 4-Amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE) |
US9840507B2 (en) | 2010-12-22 | 2017-12-12 | Janssen Pharmaceutica, Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
US9845326B2 (en) | 2011-03-09 | 2017-12-19 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors |
US10106524B2 (en) | 2014-12-18 | 2018-10-23 | Janssen Pharmaceutica Nv | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase |
WO2019208693A1 (fr) | 2018-04-27 | 2019-10-31 | Shionogi & Co., Ltd. | Dérivés de tétrahydropyranooxazine présentant une activité inhibitrice sélective de bace1 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014120658A1 (fr) | 2013-01-29 | 2014-08-07 | Amgen Inc. | Dérivés de 3-amino-5,6-dihydro-2h-1,4-thiazine multicycliques condensés et leur utilisation à titre d'inhibiteurs de bêta-sécrétase |
TWI639607B (zh) | 2013-06-18 | 2018-11-01 | 美國禮來大藥廠 | Bace抑制劑 |
US9096615B2 (en) | 2013-07-30 | 2015-08-04 | Amgen Inc. | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof |
WO2015132141A1 (fr) * | 2014-03-03 | 2015-09-11 | F. Hoffmann-La Roche Ag | Dérivés de 1,3-oxazine-2-amine agissant comme inhibiteurs de bace pour le traitement de la maladie d'alzheimer |
WO2017024180A1 (fr) | 2015-08-06 | 2017-02-09 | Amgen Inc. | Composés thiazin-2-amine fusionnée à un vinyl fluorure cyclopropyle en tant qu'inhibiteurs de la bêta-secrétase et leurs procédés d'utilisation |
MX2019007103A (es) | 2016-12-15 | 2019-11-05 | Amgen Inc | Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. |
CA3047288A1 (fr) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Derives de thiazine en tant qu'inhibiteurs de beta-secretase et procedes d'utilisation |
MX2019007104A (es) | 2016-12-15 | 2019-11-05 | Amgen Inc | Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso. |
CA3047285A1 (fr) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Derives de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de beta-secretase et procedes d'utilisation |
AU2017376441B2 (en) | 2016-12-15 | 2021-10-14 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
JP2022532810A (ja) * | 2018-07-06 | 2022-07-20 | 塩野義製薬株式会社 | 選択的bace1阻害活性を有する縮合複素環誘導体 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005058311A1 (fr) | 2003-12-15 | 2005-06-30 | Schering Corporation | Inhibiteurs de protease aspartyle heterocyclique |
WO2006065277A2 (fr) | 2004-12-13 | 2006-06-22 | Schering Corporation | Inhibiteurs d'aspartyle protease heterocycliques |
WO2007049532A1 (fr) | 2005-10-25 | 2007-05-03 | Shionogi & Co., Ltd. | Derive aminodihydrothiazine |
WO2007058583A2 (fr) | 2005-11-15 | 2007-05-24 | Astrazeneca Ab | Composes et leurs utilisations |
WO2008103351A2 (fr) | 2007-02-23 | 2008-08-28 | Schering Corporation | Inhibiteurs de la protéase d'aspartyle hétérocycliques |
WO2008133273A1 (fr) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Composition pharmaceutique pour le traitement de la maladie d'alzheimer |
WO2008133274A1 (fr) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Dérivés d'aminodihydrothiazine substitués par des groupes cycliques |
WO2009091016A1 (fr) | 2008-01-18 | 2009-07-23 | Eisai R & D Management Co., Ltd. | Dérivé d'aminodihydrothiazine condensée |
WO2009103626A1 (fr) | 2008-02-18 | 2009-08-27 | F. Hoffmann-La Roche Ag | Dérivés de 4,5-dihydrooxazol-2-ylamine |
WO2009134617A1 (fr) | 2008-05-02 | 2009-11-05 | Eli Lilly And Company | Dérivés d’aminodihydrothiazine en tant qu’inhibiteurs de bace destinés au traitement de la maladie d’alzheimer |
WO2009151098A1 (fr) | 2008-06-13 | 2009-12-17 | 塩野義製薬株式会社 | DÉRIVÉ HÉTÉROCYCLIQUE CONTENANT DU SOUFRE AYANT UNE ACTIVITÉ INHIBANT LA β-SÉCRÉTASE |
Family Cites Families (212)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2899426A (en) | 1959-08-11 | Synthesis of l | ||
US3235551A (en) | 1966-02-15 | Novel derivatives of | ||
US3227713A (en) | 1966-01-04 | Azine derivatives | ||
US3115494A (en) | 1961-10-13 | 1963-12-24 | Mcneilab Inc | 2-amino-5, 6-dihydro-4ii-1, 3-oxazines and a process for their preparation |
BE637923A (fr) | 1962-09-29 | |||
US3636116A (en) | 1968-09-03 | 1972-01-18 | Dow Chemical Co | 1 2-substituted indene compounds |
SU465792A3 (ru) | 1968-11-06 | 1975-03-30 | Хиноин Гиогисцер-Ес Вегиесцети Термекек Гиара Рт (Фирма) | Способ получени гетероциклических соединений |
US3577428A (en) | 1969-04-14 | 1971-05-04 | Colgate Palmolive Co | 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines |
US3719674A (en) | 1971-02-08 | 1973-03-06 | Dow Chemical Co | 1,2-substituted indene compounds |
DE2426653C3 (de) | 1974-06-01 | 1982-05-06 | Bayer Ag, 5090 Leverkusen | Derivate des 2-Amino-1,3-thiazins |
DD140144A1 (de) | 1978-11-08 | 1980-02-13 | Horst Hartmann | Verfahren zur herstellung von p-aminophenylsubstituierten 2-amino-1,3-thiaziniumsalzen |
US4311840A (en) | 1980-11-13 | 1982-01-19 | E. R. Squibb & Sons, Inc. | 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones |
JPS62120374A (ja) | 1985-11-20 | 1987-06-01 | Yoshitomi Pharmaceut Ind Ltd | 1,3−チアジンまたは1,3−オキサジン誘導体 |
JPH0231792Y2 (fr) | 1986-01-21 | 1990-08-28 | ||
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
CA1332151C (fr) | 1988-01-28 | 1994-09-27 | Roman Amrein | Utilisation d'un benzamide dans le traitement d'un trouble cognitif |
US5236942A (en) | 1990-04-19 | 1993-08-17 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful in the treatment of Altzheimer's dementia |
US5328915A (en) | 1992-09-17 | 1994-07-12 | E. I. Du Pont De Nemours And Company | Arthropodicidal amidrazone ureas |
IL107771A0 (en) | 1992-11-27 | 1994-02-27 | Wellcome Found | Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation |
AU7705694A (en) | 1993-10-04 | 1995-05-01 | Glaxo Wellcome House | Substituted urea and isothiourea derivatives as no synthase inhibitors |
GB9418912D0 (en) | 1994-09-20 | 1994-11-09 | Fisons Corp | Pharmaceutically active compounds |
WO1996014842A1 (fr) | 1994-11-15 | 1996-05-23 | Merck & Co., Inc. | Heterocycles a substitutions utilises en tant qu'inhibiteurs de la synthetase d'oxyde nitrique |
DE4442116A1 (de) | 1994-11-25 | 1996-05-30 | Cassella Ag | 2-Amino-1,3-thiazine als Hemmstoffe der Stickstoffmonoxid-Synthase |
AU2629795A (en) | 1994-12-12 | 1996-07-03 | Chugai Seiyaku Kabushiki Kaisha | Aniline derivative having the effect of inhibiting nitrogen monoxide synthase |
JPH08333258A (ja) | 1994-12-14 | 1996-12-17 | Japan Tobacco Inc | チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤 |
DE4444930A1 (de) | 1994-12-16 | 1996-06-27 | Cassella Ag | 2-Amino-1,3-thiazepine und deren Verwendung als Hemmstoffe der Stickstoffmonoxid-Synthase |
TW372967B (en) * | 1994-12-27 | 1999-11-01 | Kanebo Ltd | 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof |
RU2140910C1 (ru) | 1995-08-11 | 1999-11-10 | Пфайзер Инк. | Тригидрат метансульфоната (1s,2s)-1-(4-гидроксифенил)-2-(4-гидрокси-4- фенилпиперидин-1-ил)-1-пропанола |
JPH0967355A (ja) | 1995-08-31 | 1997-03-11 | Tokyo Tanabe Co Ltd | チアジン誘導体、チアゾール誘導体及びそれらの製造方法 |
MX9604165A (es) | 1995-09-18 | 1997-10-31 | Sankyo Co | Nuevos derivados de urea que tienen actividad inhibidora de acil-coa: colesterol acil transferasa; su preparacion y su uso terapeutico y profilactico. |
NZ319673A (en) | 1995-10-17 | 2000-06-23 | Astra Pharma Prod | Quinazoline compounds for inflammatory disorders such rheumatoid arthritis or osteoarthritis |
WO1997038977A1 (fr) | 1996-04-13 | 1997-10-23 | Astra Pharmaceuticals Ltd. | Amino-isoquinolines et derives d'aminothienopyridine et leur utilisation en tant qu'agents anti-inflammatoires |
US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US5952374A (en) | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
SE9703693D0 (sv) | 1997-10-10 | 1997-10-10 | Astra Pharma Prod | Novel combination |
TW460460B (en) | 1997-11-04 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Heterocyclic compounds having NOS inhibitory activities |
US6294695B1 (en) | 1998-03-26 | 2001-09-25 | Mount Sinai School Of Medicine Of The City University Of New York | Aminobenzoic acid derivatives having anti-tumorigenic activity methods of making and using the same |
AUPP285898A0 (en) | 1998-04-07 | 1998-04-30 | Fujisawa Pharmaceutical Co., Ltd. | Amido derivatives |
SE9802333D0 (sv) | 1998-06-29 | 1998-06-29 | Astra Pharma Prod | Novel combination |
US7375125B2 (en) | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
MX226123B (es) | 1999-09-17 | 2005-02-07 | Millennium Pharm Inc | Benzamidas e inhibidores del factor xa relacionadas. |
CA2404858A1 (fr) | 2000-04-12 | 2001-10-25 | Minerva Biotechnologies Corporation | Traitement des maladies neurodegeneratives |
WO2001087293A1 (fr) | 2000-05-19 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Inhibiteurs de la ?-secretase |
WO2003040115A1 (fr) | 2001-11-09 | 2003-05-15 | Aventis Pharma S.A. | Derives de 2-amino-thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible |
US6420566B2 (en) | 2000-06-09 | 2002-07-16 | Aventis Pharma S.A. | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof |
US6713276B2 (en) | 2000-06-28 | 2004-03-30 | Scios, Inc. | Modulation of Aβ levels by β-secretase BACE2 |
EP1363890A4 (fr) | 2001-02-07 | 2009-06-10 | Ore Pharmaceuticals Inc | Composes de liaison au recepteur de la melanocortine-4 et procedes d'utilisation de tels composes |
WO2002088101A2 (fr) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de bace |
US6562783B2 (en) | 2001-05-30 | 2003-05-13 | Neurologic, Inc. | Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors |
AP2004003049A0 (en) | 2001-11-08 | 2004-06-30 | Elan Pharm Inc | N,N' -substituted-1,3-diamino -2-hydroxypropane derivatives. |
JP4342309B2 (ja) | 2001-11-09 | 2009-10-14 | アベンティス・ファーマ・ソシエテ・アノニム | 誘導型no−シンターゼ阻害剤としての2−アミノ−4−ピリジルメチル−チアゾリン誘導体の使用 |
BR0206363A (pt) | 2001-11-09 | 2003-12-23 | Aventis Pharma Sa | Utilização de deerivados de 2-amino-4-heteroariletiltiazolina como inibidores de no-sintase indutìvel |
WO2003082191A2 (fr) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | 2,3-diphenyl-pyridines substituees |
EP1517688A2 (fr) | 2002-06-19 | 2005-03-30 | Solvay Pharmaceuticals GmbH | Medicament pour traiter des affections impliquant une inhibition ou une baisse d'activite de proteines transporteuses de bicarbonate regulant le ph |
WO2004009549A2 (fr) | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines utiles pour traiter des maladies du systeme nerveux central |
AU2003254844A1 (en) | 2002-08-09 | 2004-02-25 | Takeda Chemical Industries, Ltd. | Substituted amino compounds and use thereof |
TW200502221A (en) | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
JP2006096665A (ja) | 2002-10-29 | 2006-04-13 | Ono Pharmaceut Co Ltd | 脊柱管狭窄症治療剤 |
JP2004149429A (ja) | 2002-10-29 | 2004-05-27 | Takeda Chem Ind Ltd | インドール化合物およびその用途 |
DE60329316D1 (de) | 2002-11-12 | 2009-10-29 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
RU2252936C2 (ru) | 2002-12-05 | 2005-05-27 | Институт физиологически активных веществ РАН | S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты) |
US7429603B2 (en) | 2003-04-25 | 2008-09-30 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
GB0324498D0 (en) | 2003-07-21 | 2003-11-26 | Aventis Pharma Inc | Heterocyclic compounds as P2X7 ion channel blockers |
WO2005032493A2 (fr) | 2003-10-07 | 2005-04-14 | Renovis, Inc. | Composes d'amides utilises en tant que ligands de canaux ioniques et utilisations correspondantes |
EP1732906A4 (fr) | 2004-03-30 | 2007-11-21 | Merck & Co Inc | Composes de 2-aminothiazole utiles en tant qu'inhibiteurs de l'aspartyle-protease |
CA2564751A1 (fr) | 2004-04-30 | 2005-11-24 | Schering Corporation | Substances modulatrices d'un recepteur neuropeptidique |
KR20070026811A (ko) | 2004-06-16 | 2007-03-08 | 와이어쓰 | 베타-세크리타제 억제제로서의 디페닐이미다조피리미딘 및디페닐이미다졸 아민 |
AU2005277283A1 (en) | 2004-08-23 | 2006-03-02 | Merck Sharp & Dohme Corp. | Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
CA2579472A1 (fr) | 2004-09-14 | 2006-03-23 | The Genetics Company, Inc. | Derives d'hydrazone et leur utilisation comme inhibiteurs de la beta-secretase |
WO2006041404A1 (fr) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Composes amino substitues et utilisation de ces compose |
US20090062282A1 (en) | 2004-10-15 | 2009-03-05 | Astrazeneca Ab | Substituted Amino-Pyrimidones and Uses Thereof |
US20080287399A1 (en) | 2004-12-14 | 2008-11-20 | Astrazeneca Ab | Substituted Aminopyridines and Uses Thereof |
TWI441819B (zh) | 2005-01-07 | 2014-06-21 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之化合物 |
WO2006076284A2 (fr) | 2005-01-14 | 2006-07-20 | Wyeth | AMINO-IMIDAZOLONES DESTINES A L'INHIBITION DE LA ß-SECRETASE |
WO2006088705A1 (fr) | 2005-02-14 | 2006-08-24 | Wyeth | Guanidine de terphenyle en tant qu'inhibiteurs de la $g(b)-secretase |
CN101146769A (zh) | 2005-02-14 | 2008-03-19 | 惠氏公司 | 作为β-分泌酶抑制剂的唑基酰基胍 |
WO2006088694A1 (fr) | 2005-02-14 | 2006-08-24 | Wyeth | THIÉNYL- ET FURYLACYLGUANIDINE SUBSTITUÉES ET MÉTHODES D'EMPLOI DESDITS COMPOSÉS EN TANT QUE RÉGULATEURS DE LA β-SECRÉTASE |
CN101142194B (zh) | 2005-03-14 | 2012-10-10 | 顶点制药有限责任公司 | 吲哚衍生物,组合物及用作β-分泌酶抑制剂的方法 |
WO2006138217A1 (fr) | 2005-06-14 | 2006-12-28 | Schering Corporation | Inhibiteurs d'aspartyl protease |
KR20080031189A (ko) | 2005-06-14 | 2008-04-08 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
ES2436795T3 (es) | 2005-06-14 | 2014-01-07 | Merck Sharp & Dohme Corp. | Inhibidores heterocíclicos de aspartil proteasa, preparación y uso de los mismos |
US20060281712A1 (en) | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
WO2007002220A2 (fr) | 2005-06-21 | 2007-01-04 | Bristol-Myers Squibb Company | Guanidines d'acyle acetamide amine en tant qu'inhibiteurs de beta-secretase |
AU2006266167A1 (en) | 2005-06-30 | 2007-01-11 | Wyeth | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation |
TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
EP1915339A1 (fr) * | 2005-08-11 | 2008-04-30 | Boehringer Ingelheim International GmbH | Inhibiteurs de la beta-secretase pour traiter la maladie d'alzheimer |
JP2009509957A (ja) | 2005-09-26 | 2009-03-12 | ワイス | β−セクレターゼ阻害剤としてのアミノ−5−[4−(ジフルオロメトキシ)フェニル]−5−フェニルイミダゾロン化合物 |
JP2009515951A (ja) | 2005-11-15 | 2009-04-16 | アストラゼネカ・アクチエボラーグ | 新規な2−アミノピリミジノンまたは2−アミノピリジノン誘導体およびそれらの使用 |
US20090215801A9 (en) | 2005-11-15 | 2009-08-27 | Astrazeneca Ab, Sodertaije, Swedenastex Thereapeutics Ltd | Novel 2-Aminopyrimidinone Derivatives And Their Use |
WO2007058601A1 (fr) | 2005-11-21 | 2007-05-24 | Astrazeneca Ab | Nouveaux composes 2-amino-imidazole-4-one et leur utilisation dans la fabrication d'un medicament destine a etre utilise dans le traitement d'une deficience cognitive, la maladie d'alzheimer, le neurodegenerescence et la demence |
TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
JP2009520027A (ja) | 2005-12-19 | 2009-05-21 | ワイス | 2−アミノ−5−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用 |
AR058381A1 (es) | 2005-12-19 | 2008-01-30 | Astrazeneca Ab | Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica |
PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
US7868022B2 (en) | 2006-02-06 | 2011-01-11 | Janssen Pharmaceutica Nv | 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
US7776882B2 (en) | 2006-02-06 | 2010-08-17 | Baxter Ellen W | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
JP2009532464A (ja) | 2006-04-05 | 2009-09-10 | アストラゼネカ・アクチエボラーグ | 2−アミノピリミジン−4−オン及びAβ−関連の病理を治療又は予防するためのその使用 |
TW200808751A (en) | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
MX2008013533A (es) | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Compuestos heterociclicos como inhibidores de c-fms cinasa. |
AR061264A1 (es) | 2006-06-12 | 2008-08-13 | Schering Corp | Inhibidores de aspartil-proteasas derivados de pirimidina, composiciones farmaceuticas que los contienen y usos para tratar enfermedades cognitivas o neurodegenerativas, y como inhibidores del virus vih. |
US20080021217A1 (en) | 2006-07-20 | 2008-01-24 | Allen Borchardt | Heterocyclic inhibitors of rho kinase |
TW200817406A (en) | 2006-08-17 | 2008-04-16 | Wyeth Corp | Imidazole amines as inhibitors of β-secretase |
US8093254B2 (en) | 2006-12-12 | 2012-01-10 | Schering Corporation | Aspartyl protease inhibitors |
EP2061771A1 (fr) | 2006-12-12 | 2009-05-27 | Schering Corporation | Inhibiteurs de la protéase aspartyle contenant un système de noyau tricyclique |
TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
KR101335845B1 (ko) | 2007-02-15 | 2013-12-02 | 에프. 호프만-라 로슈 아게 | Taar1 리간드로서의 2-아미노옥사졸린 |
GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
JP4846769B2 (ja) | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2009064418A1 (fr) | 2007-11-14 | 2009-05-22 | Amgen Inc. | Composés d'hydroxyéthylamine substituée en tant que modulateurs de bêta-sécrétase et leurs procédés d'utilisation |
BRPI0906625A2 (pt) | 2008-01-28 | 2015-07-14 | Janssen Pharmaceutica Nv | Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace) |
AU2009209147B2 (en) | 2008-01-29 | 2013-03-14 | Janssen Pharmaceutica Nv | 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (BACE) |
US8071766B2 (en) | 2008-02-01 | 2011-12-06 | Takeda Pharmaceutical Company Limited | HSP90 inhibitors |
JP2011518225A (ja) | 2008-04-22 | 2011-06-23 | シェーリング コーポレイション | Bace−1阻害剤としてのフェニル置換2−イミノ−3−メチルピロロピリミジノン化合物、組成物、およびそれらの使用 |
WO2010013302A1 (fr) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Dérivé de spiroaminodihydrothiazine |
AU2009277485B2 (en) | 2008-07-28 | 2013-05-02 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
US20110251172A1 (en) | 2008-08-13 | 2011-10-13 | Rivkin Alexey A | Purine derivatives for treatment of alzheimer's disease |
US8685972B2 (en) | 2008-08-13 | 2014-04-01 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives for treatment of alzheimer's disease |
EP2332943B1 (fr) | 2008-09-30 | 2015-04-22 | Eisai R&D Management Co., Ltd. | Dérivé d'aminodihydrothiazine fusionné inédit |
JPWO2010047372A1 (ja) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Bace1阻害活性を有する2−アミノピリミジン−4−オンおよび2−アミノピリジン誘導体 |
WO2010056194A1 (fr) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | Dérivés de 5h-pyrrolo [ 3, 4-b] pyridine et leur utilisation |
US20100125087A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 575 |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
TW201040141A (en) | 2009-03-31 | 2010-11-16 | Shionogi & Co | Isothiourea derivatives or isourea derivatives having BACE1 inhibitory activity |
KR101123178B1 (ko) | 2009-04-09 | 2012-06-13 | (주)에스메디 | 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
EP2459565B1 (fr) | 2009-05-07 | 2018-05-02 | The Board of Trustees of The Leland Stanford Junior University | Dérivés de saxitoxin, procédés et compositions pour étudier, visualiser par imagerie et traiter la douleur |
US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
UY32799A (es) | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
WO2011044184A1 (fr) | 2009-10-08 | 2011-04-14 | Schering Corporation | Composés hétérocycliques de type imino-pentafluorosulfure utilisés en tant qu'inhibiteurs de bace1, compositions en contenant et leur utilisation |
EP2485920B1 (fr) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Composés hétérocycliques iminopentafluorosoufrés en tant qu'inhibiteurs de bace-1, compositions et leur utilisation |
US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
US20120238557A1 (en) | 2009-11-13 | 2012-09-20 | Shionogi & Co., Ltd. | Aminothiazine or aminooxazine derivative having amino linker |
EP2509983B1 (fr) | 2009-11-16 | 2014-09-17 | Merck Sharp & Dohme Corp. | Composés tricycliques condensés possédant une activité antagoniste des récepteurs a2a de l'adénosine |
JP5554346B2 (ja) | 2009-12-09 | 2014-07-23 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
US20120245154A1 (en) | 2009-12-09 | 2012-09-27 | Shionogi & Co., Ltd. | Substituted aminothiazine derivative |
US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
WO2011071135A1 (fr) | 2009-12-11 | 2011-06-16 | 塩野義製薬株式会社 | Dérivé d'oxazine |
WO2011071109A1 (fr) | 2009-12-11 | 2011-06-16 | 塩野義製薬株式会社 | Composé hétérocyclique fusionné comportant un groupement amino |
EP2518059A4 (fr) | 2009-12-24 | 2013-05-29 | Shionogi & Co | Dérivé de 4-amino-1,3-thiazine ou oxazine |
PE20121640A1 (es) | 2009-12-31 | 2012-12-17 | Novartis Ag | Derivados de pirazina como inhibidores de bace |
US8673894B2 (en) | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
BR112012031337A2 (pt) | 2010-06-09 | 2016-10-25 | Janssen Pharmaceutica Nv | derivados de 5-amino-3,6-di-hidro-1h-pirazin-2-ona úteis como inibidores de beta-secretase (bace) |
KR101730937B1 (ko) | 2010-06-09 | 2017-04-27 | 얀센 파마슈티카 엔.브이. | 베타-세크레타아제(bace) 저해제로 유용한 5,6-디하이드로-2h-[1,4]옥사진-3-일-아민 유도체 |
JP2013529664A (ja) | 2010-06-28 | 2013-07-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アルツハイマー病および他の型の認知症の処置に有用な3−アミノ−5,6−ジヒドロ−1h−ピラジン−2−オン誘導体 |
WO2012006953A1 (fr) | 2010-07-13 | 2012-01-19 | Novartis Ag | Dérivés de l'oxazine et leur utilisation dans le traitement de troubles neurologiques |
US8815881B2 (en) | 2010-08-09 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds |
MY160138A (en) | 2010-09-22 | 2017-02-28 | Janssen Pharmaceutica Nv | 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
EP2634188A4 (fr) | 2010-10-29 | 2014-05-07 | Shionogi & Co | Dérivé d'aminodihydropyrimidine fusionnée |
US8927721B2 (en) | 2010-10-29 | 2015-01-06 | Shionogi & Co., Ltd. | Naphthyridine derivative |
SG191097A1 (en) | 2010-12-22 | 2013-08-30 | Janssen Pharmaceutica Nv | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
US8524897B2 (en) | 2011-01-12 | 2013-09-03 | Novartis Ag | Crystalline oxazine derivative |
CN103429589A (zh) | 2011-01-12 | 2013-12-04 | 诺瓦提斯公司 | 噁嗪衍生物及其在治疗神经障碍中的用途 |
CA2824220C (fr) | 2011-01-13 | 2020-09-01 | Novartis Ag | Nouveaux derives heterocycliques et leur utilisation dans le traitement de troubles neurologiques |
US20140128385A1 (en) | 2011-01-13 | 2014-05-08 | Novartis Ag | Bace-2 inhibitors for the treatment of metabolic disorders |
US9242943B2 (en) | 2011-01-18 | 2016-01-26 | Siena Biotech S.P.A. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
US8399459B2 (en) | 2011-02-02 | 2013-03-19 | Hoffmann-La Roche Inc. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
US8815841B2 (en) | 2011-02-18 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
KR102012671B1 (ko) | 2011-03-01 | 2019-08-21 | 얀센 파마슈티카 엔.브이. | 베타-세크레타제(BACE)의 억제제로서 유용한 6,7-디하이드로-피라졸로[1,5-a]피라진-4-일아민 유도체 |
US9067924B2 (en) | 2011-03-04 | 2015-06-30 | Hoffmann-La Roche Inc. | 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors |
MX340031B (es) | 2011-03-09 | 2016-06-21 | Janssen Pharmaceutica Nv | Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1-ilamina utiles como inhibidores de beta-secretasa (bace). |
US8748418B2 (en) | 2011-03-18 | 2014-06-10 | Hoffmann-La Roche Inc. | 1,4-oxazepines as BACE1 and/or BACE2 inhibitors |
US8877744B2 (en) | 2011-04-04 | 2014-11-04 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
WO2012147763A1 (fr) † | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | Dérivé d'oxazine et inhibiteur de bace 1 le contenant |
WO2012147762A1 (fr) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | Dérivé de pyridine et inhibiteur de bace-1 le contenant |
US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
WO2012162334A1 (fr) | 2011-05-24 | 2012-11-29 | Bristol-Myers Squibb Company | Composés destinés à la réduction de la production de bêta-amyloïdes |
US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
JP2012250933A (ja) † | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
WO2012168164A1 (fr) | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | Halogéno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2 |
RU2599256C2 (ru) † | 2011-06-07 | 2016-10-10 | Ф. Хоффманн-Ля Рош Аг | [1,3]оксазины |
UY34278A (es) † | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
US8476264B2 (en) † | 2011-09-21 | 2013-07-02 | Hoffmann-La Roche Inc. | N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors |
UA111749C2 (uk) | 2011-12-05 | 2016-06-10 | Янссен Фармацевтика Нв | Похідні 6-дифторметил-5,6-дигідро-2h-[1,4]оксазин-3-аміну |
CN103974940B (zh) | 2011-12-06 | 2016-08-24 | 詹森药业有限公司 | 5-(3-氨基苯基)-5-烷基-5,6-二氢-2h-[1,4]噁嗪-3-胺衍生物 |
CN104066727B (zh) † | 2012-01-26 | 2019-04-26 | 霍夫曼-拉罗奇有限公司 | 氟甲基-5,6-二氢-4h-[1,3]噁嗪类 |
US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
JP2015514073A (ja) † | 2012-03-20 | 2015-05-18 | エラン ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニー | スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンbace阻害剤、ならびにその組成物および使用 |
CA2872181A1 (fr) † | 2012-06-26 | 2014-01-03 | F. Hoffmann-La Roche Ag | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 |
WO2014010748A1 (fr) | 2012-07-10 | 2014-01-16 | Shionogi & Co., Ltd. | Dérivé de cyclopropane présentant une activité inhibitrice de bace1 |
WO2014065434A1 (fr) † | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1 |
JP2014101354A (ja) † | 2012-10-24 | 2014-06-05 | Shionogi & Co Ltd | Bace1阻害作用を有するオキサジン誘導体 |
JP2014101353A (ja) † | 2012-10-26 | 2014-06-05 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
WO2014098831A1 (fr) | 2012-12-19 | 2014-06-26 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines à titre d'inhibiteurs de bace1 et leur utilisation pour réduire la production des bêta-amyloïdes |
CA2896185A1 (fr) † | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Fluoro-[1,3]oxazines servant d'inhibiteurs de la bace1 |
WO2014134341A1 (fr) † | 2013-03-01 | 2014-09-04 | Amgen Inc. | Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants |
EP2964644B1 (fr) † | 2013-03-08 | 2018-12-26 | Amgen, Inc. | Composés perfluorés à base de 1,3-oxazin-2-amine condensée avec un cyclopropyle en tant qu'inhibiteurs de la bêta-secrétase et leurs procédés d'utilisation |
JP6155537B2 (ja) † | 2013-03-22 | 2017-07-05 | エルジー・ケム・リミテッド | 導電性パターン積層体およびその製造方法、並びに導電性パターン積層体を含む電子装置およびタッチスクリーン |
WO2014166906A1 (fr) † | 2013-04-11 | 2014-10-16 | F. Hoffmann-La Roche Ag | Inhibiteurs de bace1 |
WO2015132141A1 (fr) † | 2014-03-03 | 2015-09-11 | F. Hoffmann-La Roche Ag | Dérivés de 1,3-oxazine-2-amine agissant comme inhibiteurs de bace pour le traitement de la maladie d'alzheimer |
TW201623295A (zh) † | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
WO2016001266A1 (fr) † | 2014-07-04 | 2016-01-07 | F. Hoffmann-La Roche Ag | Fluoro-[1,3]oxazines en tant qu'inhibiteurs de bace1 |
WO2016012384A1 (fr) † | 2014-07-22 | 2016-01-28 | F. Hoffmann-La Roche Ag | Amidines de trifluormethyloxazine utilisées comme inhibiteurs de bace1 |
WO2017061534A1 (fr) † | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dérivés de dihydrothiazine |
JP2017071603A (ja) † | 2015-10-09 | 2017-04-13 | 塩野義製薬株式会社 | ジヒドロチアジンまたはジヒドロオキサジン誘導体を含有する医薬組成物 |
CA3047285A1 (fr) † | 2016-12-15 | 2018-06-21 | Amgen Inc. | Derives de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de beta-secretase et procedes d'utilisation |
AU2017376441B2 (en) † | 2016-12-15 | 2021-10-14 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
-
2010
- 2010-12-10 WO PCT/JP2010/072193 patent/WO2011071135A1/fr active Application Filing
- 2010-12-10 KR KR1020127014809A patent/KR20120104570A/ko not_active Application Discontinuation
- 2010-12-10 ES ES10836054T patent/ES2590038T5/es active Active
- 2010-12-10 CA CA2783958A patent/CA2783958A1/fr not_active Abandoned
- 2010-12-10 AU AU2010328975A patent/AU2010328975B2/en not_active Ceased
- 2010-12-10 EP EP10836054.6A patent/EP2511268B2/fr active Active
- 2010-12-10 RU RU2012129168/04A patent/RU2012129168A/ru not_active Application Discontinuation
- 2010-12-10 BR BR112012013854A patent/BR112012013854A2/pt not_active IP Right Cessation
- 2010-12-10 US US13/513,839 patent/US8999980B2/en not_active Expired - Fee Related
- 2010-12-10 JP JP2011545253A patent/JPWO2011071135A1/ja not_active Withdrawn
- 2010-12-10 UA UAA201208561A patent/UA110467C2/uk unknown
- 2010-12-10 CN CN2010800648635A patent/CN102834384A/zh active Pending
- 2010-12-10 MX MX2012006491A patent/MX2012006491A/es active IP Right Grant
- 2010-12-10 TW TW099143216A patent/TWI488852B/zh not_active IP Right Cessation
-
2012
- 2012-05-23 ZA ZA2012/03777A patent/ZA201203777B/en unknown
-
2013
- 2013-05-17 ZA ZA2013/03603A patent/ZA201303603B/en unknown
-
2015
- 2015-02-20 US US14/627,700 patent/US9290466B2/en not_active Expired - Fee Related
- 2015-09-03 JP JP2015173564A patent/JP2016028057A/ja not_active Ceased
-
2016
- 2016-02-11 US US15/041,683 patent/US9656974B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005058311A1 (fr) | 2003-12-15 | 2005-06-30 | Schering Corporation | Inhibiteurs de protease aspartyle heterocyclique |
WO2006065277A2 (fr) | 2004-12-13 | 2006-06-22 | Schering Corporation | Inhibiteurs d'aspartyle protease heterocycliques |
WO2007049532A1 (fr) | 2005-10-25 | 2007-05-03 | Shionogi & Co., Ltd. | Derive aminodihydrothiazine |
WO2007058583A2 (fr) | 2005-11-15 | 2007-05-24 | Astrazeneca Ab | Composes et leurs utilisations |
WO2008103351A2 (fr) | 2007-02-23 | 2008-08-28 | Schering Corporation | Inhibiteurs de la protéase d'aspartyle hétérocycliques |
WO2008133273A1 (fr) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Composition pharmaceutique pour le traitement de la maladie d'alzheimer |
WO2008133274A1 (fr) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Dérivés d'aminodihydrothiazine substitués par des groupes cycliques |
WO2009091016A1 (fr) | 2008-01-18 | 2009-07-23 | Eisai R & D Management Co., Ltd. | Dérivé d'aminodihydrothiazine condensée |
WO2009103626A1 (fr) | 2008-02-18 | 2009-08-27 | F. Hoffmann-La Roche Ag | Dérivés de 4,5-dihydrooxazol-2-ylamine |
WO2009134617A1 (fr) | 2008-05-02 | 2009-11-05 | Eli Lilly And Company | Dérivés d’aminodihydrothiazine en tant qu’inhibiteurs de bace destinés au traitement de la maladie d’alzheimer |
WO2009151098A1 (fr) | 2008-06-13 | 2009-12-17 | 塩野義製薬株式会社 | DÉRIVÉ HÉTÉROCYCLIQUE CONTENANT DU SOUFRE AYANT UNE ACTIVITÉ INHIBANT LA β-SÉCRÉTASE |
Non-Patent Citations (4)
Title |
---|
"Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A", vol. 1, 1987 |
RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, vol. 39, no. 12, 2003, pages 1789 - 1791 |
See also references of EP2511268A4 * |
THEODORA W GREENE: "Protective Groups in organic Synthesis", JOHN WILEY & SONS |
Cited By (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8183252B2 (en) | 2003-12-15 | 2012-05-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US8815851B2 (en) | 2005-10-25 | 2014-08-26 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
US8173642B2 (en) | 2005-10-25 | 2012-05-08 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
US8633188B2 (en) | 2005-10-25 | 2014-01-21 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
US8546380B2 (en) | 2005-10-25 | 2013-10-01 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
US9029358B2 (en) | 2005-10-25 | 2015-05-12 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
US8884062B2 (en) | 2007-04-24 | 2014-11-11 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
US8168630B2 (en) | 2007-04-24 | 2012-05-01 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
US8895548B2 (en) | 2007-04-24 | 2014-11-25 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating alzheimer's disease |
US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
US9650371B2 (en) | 2008-06-13 | 2017-05-16 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
US9273053B2 (en) | 2008-06-13 | 2016-03-01 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity |
US8703785B2 (en) | 2008-10-22 | 2014-04-22 | Shionogi & Co., Ltd. | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity |
US8207164B2 (en) | 2009-07-24 | 2012-06-26 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
US8846658B2 (en) | 2009-07-24 | 2014-09-30 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US8940748B2 (en) | 2009-10-08 | 2015-01-27 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
US9029362B2 (en) | 2009-10-08 | 2015-05-12 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as brace inhibitors, compositions, and their use |
US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
US8569310B2 (en) | 2009-10-08 | 2013-10-29 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use |
US9428475B2 (en) | 2009-10-08 | 2016-08-30 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
US9475785B2 (en) | 2009-10-08 | 2016-10-25 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use |
US8729071B2 (en) | 2009-10-08 | 2014-05-20 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use |
US9687494B2 (en) | 2009-10-08 | 2017-06-27 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
US9290466B2 (en) | 2009-12-11 | 2016-03-22 | Shionogi & Co., Ltd. | Oxazine derivatives |
US9656974B2 (en) | 2009-12-11 | 2017-05-23 | Shionogi & Co., Ltd. | Oxazine derivatives |
US9828350B2 (en) | 2010-06-09 | 2017-11-28 | Janssen Pharmaceutica Nv | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) |
US8927721B2 (en) | 2010-10-29 | 2015-01-06 | Shionogi & Co., Ltd. | Naphthyridine derivative |
US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
WO2012057248A1 (fr) | 2010-10-29 | 2012-05-03 | 塩野義製薬株式会社 | Dérivé de naphtyridine |
WO2012057247A1 (fr) | 2010-10-29 | 2012-05-03 | 塩野義製薬株式会社 | Dérivé d'aminodihydropyrimidine fusionnée |
US9840507B2 (en) | 2010-12-22 | 2017-12-12 | Janssen Pharmaceutica, Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
US8524897B2 (en) | 2011-01-12 | 2013-09-03 | Novartis Ag | Crystalline oxazine derivative |
US10035794B2 (en) | 2011-01-13 | 2018-07-31 | Novartis Ag | Heterocyclic derivatives and their use in the treatment of neurological disorders |
US10683287B2 (en) | 2011-01-13 | 2020-06-16 | Novartis Ag | Heterocyclic derivatives and their use in the treatment of neurological disorders |
US8637508B2 (en) | 2011-01-13 | 2014-01-28 | Novartis Ag | Heterocyclic derivatives and their use in the treatment of neurological disorders |
US9550758B2 (en) | 2011-01-13 | 2017-01-24 | Novartis Ag | Heterocyclic derivatives and their use in the treatment of neurological disorders |
US10301296B2 (en) | 2011-01-13 | 2019-05-28 | Novartis Ag | Heterocyclic derivatives and their use in the treatment of neurological disorders |
US8865712B2 (en) | 2011-01-13 | 2014-10-21 | Novartis Ag | Heterocyclic derivatives and their use in the treatment of neurological disorders |
WO2012107371A1 (fr) * | 2011-02-08 | 2012-08-16 | F. Hoffmann-La Roche Ag | N-[3-(5-amino-3,3a,7,7a-tétrahydro-1h-2,4-dioxa-6-azaindén-7-yl)-phényl] amides en tant qu'inhibiteurs de bace1 et/ou de bace2 |
CN103380134A (zh) * | 2011-02-08 | 2013-10-30 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的n-[3-(5-氨基-3,3a,7,7a-四氢-1h-2,4-二氧杂-6-氮杂-茚-7-基)-苯基]-酰胺 |
US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
US20120202803A1 (en) * | 2011-02-08 | 2012-08-09 | Hans Hilpert | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1h-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as bace1 and/or bace2 inhibitors |
JP2014505086A (ja) * | 2011-02-08 | 2014-02-27 | エフ.ホフマン−ラ ロシュ アーゲー | BACE1及び/又はBACE2阻害剤としてのN−[3−(5−アミノ−3,3a,7,7a−テトラヒドロ−1H−2,4−ジオキサ−6−アザ−インデン−7−イル)−フェニル]−アミド類 |
US9346811B2 (en) | 2011-03-01 | 2016-05-24 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
US9845326B2 (en) | 2011-03-09 | 2017-12-19 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors |
US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
JP2014510769A (ja) * | 2011-04-11 | 2014-05-01 | エフ.ホフマン−ラ ロシュ アーゲー | Bace1及び/又はbace2阻害剤としての1,3−オキサジン |
WO2012147763A1 (fr) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | Dérivé d'oxazine et inhibiteur de bace 1 le contenant |
WO2012147762A1 (fr) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | Dérivé de pyridine et inhibiteur de bace-1 le contenant |
CN103608345A (zh) * | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
WO2012156284A1 (fr) * | 2011-05-16 | 2012-11-22 | F. Hoffmann-La Roche Ag | 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2 |
CN103534243A (zh) * | 2011-05-16 | 2014-01-22 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的1,3-噁嗪类 |
JP2014513702A (ja) * | 2011-05-16 | 2014-06-05 | エフ.ホフマン−ラ ロシュ アーゲー | Bace1及び/又はbace2阻害剤としての1,3−オキサジン |
US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
JP2014518895A (ja) * | 2011-06-07 | 2014-08-07 | エフ.ホフマン−ラ ロシュ アーゲー | [1,3]オキサジン |
JP2014516063A (ja) * | 2011-06-07 | 2014-07-07 | エフ.ホフマン−ラ ロシュ アーゲー | Bace1及び/又はbace2阻害剤としてのハロゲン−アルキル−1,3オキサジン |
WO2012168175A1 (fr) * | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | [1,3]oxazines |
EA023261B1 (ru) * | 2011-06-07 | 2016-05-31 | Ф.Хоффманн-Ля Рош Аг | Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и(или) bace2 |
CN103608344A (zh) * | 2011-06-07 | 2014-02-26 | 霍夫曼-拉罗奇有限公司 | [1,3]噁嗪类 |
CN103608344B (zh) * | 2011-06-07 | 2016-11-23 | 霍夫曼-拉罗奇有限公司 | [1,3]噁嗪类 |
WO2012168164A1 (fr) * | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | Halogéno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2 |
US9181236B2 (en) | 2011-08-22 | 2015-11-10 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
US9163011B2 (en) | 2011-08-25 | 2015-10-20 | Novartis Ag | Oxazine derivatives and their use in the treatment of disease |
WO2013041499A1 (fr) * | 2011-09-21 | 2013-03-28 | F. Hoffmann-La Roche Ag | N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydrocyclopenta[e][1,3]oxazin-4-yl)phényl)amides utilisés comme inhibiteurs de la bace1 |
US8476264B2 (en) | 2011-09-21 | 2013-07-02 | Hoffmann-La Roche Inc. | N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors |
JP2014526534A (ja) * | 2011-09-21 | 2014-10-06 | エフ.ホフマン−ラ ロシュ アーゲー | BACE1阻害剤としてのN−(3−(2−アミノ−6,6−ジフルオロ−4,4a,5,6,7,7a−ヘキサヒドロ−シクロペンタ[e][1,3]オキサジン−4−イル)−フェニル)−アミド |
CN103827110A (zh) * | 2011-09-21 | 2014-05-28 | 霍夫曼-拉罗奇有限公司 | 作为BACE1抑制剂的N-(3-(2-氨基-6,6-二氟-4,4a,5,6,7,7a-六氢-环戊二烯并[e][1,3]噁嗪-4-基)-苯基)-酰胺 |
CN103974940A (zh) * | 2011-12-06 | 2014-08-06 | 詹森药业有限公司 | 5-(3-氨基苯基)-5-烷基-5,6-二氢-2h-[1,4]噁嗪-3-胺衍生物 |
KR20140106541A (ko) * | 2011-12-06 | 2014-09-03 | 얀센 파마슈티카 엔.브이. | 5-(3-아미노페닐)-5-알킬-5,6-디하이드로-2h-[1,4]옥사진-3-아민 유도체 |
AU2012347396B2 (en) * | 2011-12-06 | 2017-02-16 | Janssen Pharmaceutica Nv | 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2H-[1,4]oxazin-3-amine derivatives |
WO2013083556A1 (fr) * | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Dérivés de 5-(3-aminophényl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine |
CN103974940B (zh) * | 2011-12-06 | 2016-08-24 | 詹森药业有限公司 | 5-(3-氨基苯基)-5-烷基-5,6-二氢-2h-[1,4]噁嗪-3-胺衍生物 |
EA024716B1 (ru) * | 2011-12-06 | 2016-10-31 | Янссен Фармацевтика Нв | Производные 5-(3-аминофенил)-5-алкил-5,6-дигидро-2h-[1,4]оксазин-3-амина |
KR102002345B1 (ko) | 2011-12-06 | 2019-07-22 | 얀센 파마슈티카 엔.브이. | 5-(3-아미노페닐)-5-알킬-5,6-디하이드로-2h-[1,4]옥사진-3-아민 유도체 |
JP2015504906A (ja) * | 2012-01-26 | 2015-02-16 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | フルオロメチル−5,6−ジヒドロ−4h−[1,3]オキサジン |
US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
WO2014001228A1 (fr) | 2012-06-26 | 2014-01-03 | F. Hoffmann-La Roche Ag | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 |
JP2015521640A (ja) * | 2012-06-26 | 2015-07-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bace1阻害薬としてのジフルオロ−ヘキサヒドロ−シクロペンタオキサジニル類及びジフルオロ−ヘキサヒドロ−ベンゾオキサジニル類 |
CN104470915A (zh) * | 2012-06-26 | 2015-03-25 | 霍夫曼-拉罗奇有限公司 | 作为bace1抑制剂的二氟-六氢-环戊二烯并噁嗪基类和二氟-六氢-苯并噁嗪基类 |
US9556135B2 (en) | 2012-10-12 | 2017-01-31 | Amgen, Inc. | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
WO2014059185A1 (fr) | 2012-10-12 | 2014-04-17 | Amgen Inc. | Composés amino-dihydrothiazine et amino-dioxydo dihydrothiazine en tant qu'antagonistes de bêta-sécrétase et procédés d'utilisation |
WO2014065434A1 (fr) * | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1 |
US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
JP2016501827A (ja) * | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Bace1阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
US9758513B2 (en) | 2012-10-24 | 2017-09-12 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
WO2014078314A1 (fr) | 2012-11-15 | 2014-05-22 | Amgen Inc. | Composés d'amino-oxazine et d'amino-dihydrothiazine jouant le rôle de modulateurs de bêta-sécrétase et procédés d'utilisation |
US9489013B2 (en) | 2012-12-20 | 2016-11-08 | Merck Sharp & Dohme Corp. | C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use |
JP2016511258A (ja) * | 2013-03-01 | 2016-04-14 | アムジエン・インコーポレーテツド | ベータ−セクレターゼ阻害剤としてのパーフルオロ化5,6−ジヒドロ−4h−1,3−オキサジン−2−アミン化合物および使用方法 |
US9296734B2 (en) | 2013-03-01 | 2016-03-29 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
WO2014134341A1 (fr) | 2013-03-01 | 2014-09-04 | Amgen Inc. | Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants |
US9611261B2 (en) | 2013-03-08 | 2017-04-04 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
JP2016510758A (ja) * | 2013-03-08 | 2016-04-11 | アムジエン・インコーポレーテツド | β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合1,3−オキサジン−2−アミン化合物、及び使用方法 |
WO2014138484A1 (fr) | 2013-03-08 | 2014-09-12 | Amgen Inc. | Composés à base de 1,3-oxazin-2-amine fusionnée avec du cyclopropyle perfluoré utilisables en tant qu'inhibiteurs de la bêta-sécrétase et leurs procédés d'utilisation |
JP2016515638A (ja) * | 2013-04-11 | 2016-05-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bace1阻害剤 |
US9580433B2 (en) | 2013-06-12 | 2017-02-28 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
US9834559B2 (en) | 2013-06-12 | 2017-12-05 | Janssen Pharmaceutica Nv | 4-Amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE) |
US9751886B2 (en) | 2013-06-12 | 2017-09-05 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
WO2015156421A1 (fr) | 2014-04-11 | 2015-10-15 | Shionogi & Co., Ltd. | Dérivés de dihydrothiazine et de dihydrooxazine présentant une activité inhibitrice de bace1 |
KR20160141849A (ko) | 2014-04-11 | 2016-12-09 | 시오노기세이야쿠가부시키가이샤 | Bace1 저해 작용을 갖는 디하이드로티아진 및 디하이드로옥사진 유도체 |
WO2016012384A1 (fr) | 2014-07-22 | 2016-01-28 | F. Hoffmann-La Roche Ag | Amidines de trifluormethyloxazine utilisées comme inhibiteurs de bace1 |
US9550762B2 (en) | 2014-08-08 | 2017-01-24 | Amgen, Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
US10106524B2 (en) | 2014-12-18 | 2018-10-23 | Janssen Pharmaceutica Nv | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase |
WO2017061534A1 (fr) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dérivés de dihydrothiazine |
WO2019208693A1 (fr) | 2018-04-27 | 2019-10-31 | Shionogi & Co., Ltd. | Dérivés de tétrahydropyranooxazine présentant une activité inhibitrice sélective de bace1 |
KR20210003872A (ko) | 2018-04-27 | 2021-01-12 | 시오노기 앤드 컴파니, 리미티드 | 선택적 bace1 억제 활성을 갖는 테트라하이드로피라노옥사진 유도체 |
US11629154B2 (en) | 2018-04-27 | 2023-04-18 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity |
JP7353708B2 (ja) | 2018-04-27 | 2023-10-02 | 塩野義製薬株式会社 | 選択的bace1阻害活性を有するテトラヒドロピラノオキサジン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
US20150166491A1 (en) | 2015-06-18 |
EP2511268B1 (fr) | 2016-07-13 |
US20160159757A1 (en) | 2016-06-09 |
RU2012129168A (ru) | 2014-01-20 |
US20120245157A1 (en) | 2012-09-27 |
US9656974B2 (en) | 2017-05-23 |
EP2511268B2 (fr) | 2021-02-17 |
ES2590038T3 (es) | 2016-11-17 |
TWI488852B (zh) | 2015-06-21 |
UA110467C2 (uk) | 2016-01-12 |
AU2010328975B2 (en) | 2015-01-22 |
EP2511268A1 (fr) | 2012-10-17 |
AU2010328975A1 (en) | 2012-06-14 |
BR112012013854A2 (pt) | 2019-09-24 |
MX2012006491A (es) | 2012-07-03 |
JPWO2011071135A1 (ja) | 2013-04-22 |
US9290466B2 (en) | 2016-03-22 |
CA2783958A1 (fr) | 2011-06-16 |
TW201127833A (en) | 2011-08-16 |
JP2016028057A (ja) | 2016-02-25 |
ZA201203777B (en) | 2013-08-28 |
ES2590038T5 (es) | 2021-10-19 |
CN102834384A (zh) | 2012-12-19 |
EP2511268A4 (fr) | 2013-04-17 |
US8999980B2 (en) | 2015-04-07 |
ZA201303603B (en) | 2015-02-25 |
KR20120104570A (ko) | 2012-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016028057A (ja) | オキサジン誘導体 | |
JP2012250933A (ja) | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 | |
US20120258961A1 (en) | 4-amino-1,3-thiazine or oxazine derivative | |
JP5766198B2 (ja) | 縮合アミノジヒドロピリミジン誘導体 | |
JP5554346B2 (ja) | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 | |
WO2011070781A1 (fr) | Dérivé d'aminothiazine substitué | |
JPWO2011071109A1 (ja) | アミノ基を有する縮合ヘテロ環化合物 | |
WO2011058763A1 (fr) | Dérivé d'aminothiazine ou d'aminooxazine contenant un lieur amino | |
JPWO2012147763A1 (ja) | オキサジン誘導体およびそれを含有するbace1阻害剤 | |
JP2012229246A (ja) | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 | |
JP2014101353A (ja) | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 | |
WO2012057248A1 (fr) | Dérivé de naphtyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080064863.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10836054 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011545253 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010328975 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 220070 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13513839 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2010836054 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010836054 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/006491 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20127014809 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2783958 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201002732 Country of ref document: TH Ref document number: 5082/CHENP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2010328975 Country of ref document: AU Date of ref document: 20101210 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201208561 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012129168 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012013854 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012013854 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120608 |